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Abstract 
The purpose of oral toxicity study A in the EU project G-TwYST was to assess the effects of genetically 
modified (GM) maize NK 603, grown both with and without the use of RoundUp, when fed to rats for 
a period of up to two years at incorporation rates of 11% and 33% in the feed. The effects were 
assessed relative to the responses for male and female rats fed the near-isogenic non-GM maize, and 
the differences were compared, using classical and new statistical methods. 
The experimental design was a complete randomized block design with cage as the experimental 
unit. Five types of feed were administrated to cages with 2 rats in each cage. Experimental units, i.e. 
cages, were organized in blocks of 5 cages, and the feeding groups were randomized within blocks. 
Treatment identity was blinded for everyone involved in the experiments and for the statistical 
analysts until after decisions were made about outliers in the data.  
The four feeding groups with GM maize were each compared to the feeding group with non-GM 
maize for 36 variables at 3 months, 40 variables at 6 months, 44 variables at 12 months and 37 
variables at 24 months, and for males and females separately. The variables were body weight, 
growth rate, feed intake, haematology, clinical chemistry and organ weights. Only data for animals 
that survived the experiment were statistically analysed. In total, 1256 comparisons on quantitative 
variables were made. In addition, the times of death were analysed using survival analysis, and an 
analysis of mortality at 24 months. 
Using classical statistical tests at the 5% false positive level (𝛼𝛼 = 0.05), among the 1256 comparisons 
of GM groups to the non-GM group on quantitative variables, 80 (6.4%) significant differences were 
found using the parametric t-test, and 72 (5.7%) significant differences using the non-parametric 
Wilcoxon test. Using the tests at the 1% false positive level (𝛼𝛼 = 0.01), there were 13 (1.0%) 
significant differences using the t-test (lowest P-value 0.002), and also 13 (1.0%) significant 
differences using the Wilcoxon test (lowest P=value 0.005). The number of significant test results is 
therefore equal or slightly higher than the expected false positive rate of the tests, and it was 
relatively high in the 12 months data (11% for the t-tests, and 9% for the Wilcoxon tests). The 
patterns of significant results are open for toxicological interpretation.  
Statistical tests were also performed based on the factorial structure of the feeding groups using 
analysis of variance. Using statistical tests at the 5% false positive level (𝛼𝛼 = 0.05), 13 (4%) significant 
effects were found among 314 comparisons of the average of the four GM groups with the non-GM 
group, which therefore does not exceed the expected number of false positives given the nominal 
test level. More significant effects were found within the set of four GM groups. In 32 (10%) of the 
314 cases there was a significant interaction effect, i.e. the differences between the GM groups with 
and without RoundUp were dependent on the GM inclusion rate 11% or 33%. There were 22 (8%) 
significant RoundUp effects in 282 comparisons, i.e. differences of the two GM groups with RoundUp 
and the two GM groups without RoundUp. These significant RoundUp effects were relatively more 
frequent for the data after 3 months (6 out of 67, i.e. 11%) and after 12 months (11 out of 77, i.e. 
14%). The number of significant effects found for the GM inclusion rate (11 or 33%) was (6%) 22 in 
282 tests, close to the nominal test level. Overall, combined over all factorial tests the rate of 
significant results was 7% (85 out of 1192). Again, the patterns of significant results are open for 
toxicological interpretation.  
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The same type of comparisons (GM groups to non-GM group, and factorial effects) were made for 
hazard ratios from survival analyses and for mortality rates at 24 months. Among 32 one-sided tests 
for hazard ratios and 16 one-sided tests for mortality (male or female, feeding groups or factorial 
structure, animal or cage level), three tests (6%) resulted in a P-value (just) below 0.05, which is close 
to the theoretically expected rate of false positives (5%). In a factorial analysis on cages with male 
rats the hazard ratio for the two RoundUp groups was on average higher by a factor 1.73 than for the 
two GM groups without Roundup (P=0.04). With respect to mortality, a significant difference 
(P=0.03) was found in males between the Control group (36% mortality) and the GM group with 33% 
inclusion rate and RoundUp (54% mortality). This also showed up as a significantly higher average 
mortality in the two RoundUp groups compared to the two GM feeding groups without RoundUp 
(45% vs. 31%, P=0.03). For females, no significant higher hazards or mortality rates were found, 
although in fact the GM feeding groups had estimated hazards and mortalities that were equal or 
significantly lower than for the non-GM feeding group. 
Equivalence testing is in principle more adapted to the aim of safety testing than the above tests 
which are directed to find differences. The G-TwYST project has developed an equivalence testing 
method that compares the current data to historical reference data. For Study A in G-TwYST, the 
non-GM data from five 90 days studies in an earlier EU project GRACE were available as reference 
data. It was found that these data could be used as a reference basis for the 3 and 6 months data of 
the current study, but this was not the case for the 12 and 24 months data, due to a general (and 
expected) pattern of increasing between-animal variation over time. Among all 456 equivalence tests 
for the 3 and 6 months data, equivalence was shown in 433 cases (95%), which corresponds to the 
set power level (95%) of the test. Nevertheless, in all but one cases equivalence was more likely than 
non-equivalence. Most failures to show equivalence were due to a lower precision in the current 
study as compared to the historical data. Restricting the application of the equivalence tests to cases 
where the residual variance was not more than 150% of the reference residual variance, equivalence 
was established in 411 of 412 cases (99.8%). This type of equivalence testing would need its own 
collection of reference data for use with 12 months or 24 months data. 
An alternative and easier form of equivalence tests is comparison to externally given target effect 
sizes. For nine variables such values have been suggested in a recent paper. Against these values 
equivalence could be established in 211 (94%) of 224 cases, with all failures occurring for the 24 
months data, where the variation in the data was much larger. Nevertheless, in all cases equivalence 
was more likely than non-equivalence. 
The results presented in this statistical report are still to be combined with the results from 
histopathology, and are to be interpreted with respect to their toxicological implications. It is 
stressed that the statistical analysis has only looked at differences and equivalences with respect to 
external data or values. It has not used any data regarding benchmark doses that are aimed to 
distinguish between safe and unsafe values.  
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1 Introduction 
The purpose of oral toxicity study A in the EU project G-TwYST was to assess the effects of genetically 
modified (GM) maize NK 603, grown both with and without the use of RoundUp, when fed to rats for 
a period of one year (chronic toxicity study) and two years (carcinogenicity study), at incorporation 
rates of 11% and 33% in the feed. The effects of the GM maize were assessed relative to the 
responses for rats fed the near-isogenic non-GM maize. The chronic toxicity and carcinogenicity 
study ran in parallel. At 12 months part of the rats were euthanized and their organs were obtained, 
weighted and examined by the G-TwYST histopathological expert. The remaining rats were kept until 
24 months, or until premature death, and were then assessed in the same way.  
Rat weights and feed intake were measured weekly or bi-weekly. Haematology, clinical biochemistry 
in blood and urine, differential white blood cell counts, and urine volume and colour were obtained 
for subsets of animals after 3, 6, 12 and 24 months. Organ weights were observed for the animals in 
the chronic toxicity 12 month study and for the animals that did not survived the 24 month 
carcinogenicity  study.  
This report describes the main results of the statistical analysis of the data from Study A. Detailed 
results for the data obtained after 3, 6, 12 and 24 months can be found in four separate companion 
reports (Goedhart % van der Voet, 2018abcd). This main report describes the statistical methods, 
and summarises the main results. It also provides a discussion of the methodology. 
In principle, the statistical analysis was performed according to section 8 of the study plan 
(Zeljenková and Steinberg 2015). Deviations from the study plan were as follows: 
• The study plan specified a statistical analysis of data for males and females together, unless 
there were prior biological arguments or statistical indications to analyse males and females 
separately. However, toxicologists preferred separate statistical analysis of males and 
females for all variables, because it was thought that any specific non-target effect might be 
sex-specific. 
• The study plan anticipated pre-specified limits for use in equivalence testing. However, such 
limits could not be established in an early phase of the project. Therefore, an alternative 
method for equivalence testing was developed (van der Voet et al. 2017) and applied. This 
method uses historical non-GM data to obtain reference values for acceptable and normal 
variation in the observed variables. For the analysis of the data in G-TwYST, the data from 
non-GM varieties in the preceding GRACE project, which consisted of 3 months studies, were 
available as historical data. Target effect sizes for a few variables were recently proposed by 
Hong et al. (2017). Although these values have no formal status, equivalence tests were also 
performed using these effect sizes as originally planned. 
Death events were analysed in two ways: 
1. Kaplan-Meier estimates of the survival curves were plotted and hazard ratios were analysed 
using the proportional odds model.  
2. Mortality rates after 24 months were analysed using logistic regression. 
 
The remaining results, comparing each GM dose group to the non-GM control group for every 
variable, are presented according to four schemes of statistical analysis: 
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1. Equivalence tests, following the method developed in the G-TwYST project (van der Voet et 
al., 2017). 
2. For a small number of variables: equivalence tests, based on target effect sizes suggested in 
Hong et al. (2017). 
3. Classical tests, in line with OECD Guidance document 116 (2012). 
4. Standardised effect sizes, following the methods used in the GRACE project (Schmidt et al., 
2016, 2017). 
In addition, the following results from more integrated analyses were obtained: 
5. Factorial analysis, integrating over the five dose group, with main factors GmInclusionRate 
and RoundUp, and the interaction between these two factors. 
6. Correlation analysis, showing co-variation of effects for variables related to the same target 
organ. 
This report is organised as follows. Section 2 describes the data, both the data from the current study 
and the non-GM data from the GRACE studies as used in the equivalence tests. Section 3 describes 
data pre-processing procedures, such as summarising the growth and food intakes over time, outlier 
identification and assumptions checking. Section 4 presents the main results referring to the 
separate reports for details. Section 5 gives a summary and some evaluation of the methodology.  
2 Data 
2.1 Data in G-TwYST study A 
Study A is a combined chronic toxicity and carcinogenicity study in rats fed GM maize NK603. A full 
description of the data that have been measured is given in the study plan (document 632165 
A/2015/GLP, Zeljenková and Steinberg, 2015). There are five feeding groups which are administrated 
to cages with 2 rats in each cage. Experimental units, i.e. cages, are organized in blocks of 5 cages, 
and the feeding groups are randomized over cages within blocks. The design is thus a complete 
randomized block design with cage as the experimental units. There are ten blocks with male rats, 
and ten other blocks with female rats, for the one-year chronic toxicity study. In addition, there are 
25 blocks with male rats, and 25 other blocks with female rats, for the tow-year carcinogenicity 
study. For the first year of the study the total of blocks is thus 35. Most of the measurements are on 
individual animals, only feed intake is measured on the cage level. The number of planned 
observations per feeding group and sex is given in Table 1. Due to death, or missing data, the actual 
number of observations were sometimes slightly smaller. 
The definition of the five feeding groups is given in Table 2. This includes the coding of the blinded 
feeds and treatments. In this report the Group labels (Control, NK11-, NK33-, NK11+ and NK33+) will 
mostly be used. 
Male and female rats were analysed separately. Since cage is the experimental unit an analysis of 
variance employs cage means with degrees of freedom as in Table 3. The main interest is in the 
difference between each of the four GM maize feeding groups and the non-GM control feeding 
group.  
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The observed variables in Study A are given in Table 4. The variables in Table 4 exclude the following 
measurements in comparison to the study plan: 
• Histopathological data. Reason: these were excluded from this statistical analysis in the study 
plan, and will be separately reported by the histopathological expert in the G-TwYST project. 
• Periodic health status observations: morbidity, mortality, clinical signs. Rats were inspected 
twice daily for evidence of reaction to treatment or ill-health. Health status observations are 
given in Appendix 1. 
• Organ weights: thyroid, parathyroid. These were not determined.  
 
Table 1 Number of planned observations per endpoint category per feeding group and sex at 3, 
6, 12 and 24 months in study A. The number of observations at 24 months is subdivided 
in a group for animals that died prematurely and animals that survived for 24 months. 
Month 
Number of planned observations per feeding group per sex 
Weight/Feed Haematology ClinChem diffWBC Urine Organ Weights 
3 70 40 40 - 20 - 
6 70 40 40 40 20 - 
12 70 40 40 - 30 20 
24 premature all partly partly - - all 
24 survived all all all - partly - 
 
Table 2 Feeding groups and coding of feeds in study A. 
Factor Levels / Labels 
Feed coding Z-1005 Z-1002 Z-1004 Z-1003 Z-1001 
Treatment coding E B D C A 
Group Control NK11- NK33- NK11+ NK33+ 
Maize Control NK603 NK603 NK603 NK603 
AmountNK 0 11 33 11 33 
RoundUp No No No Yes Yes 
 
Table 3 Skeleton analysis of variance with degrees of freedom for cage means for a single sex. 
Source of variation 
35 cages/group 20 cages/group 10 cages/group 
d.f. d.f. d.f. 
Block stratum 34 19 9 
Block.Cage stratum 
 Group 
 Residual 
 
4 
137 
 
4 
76 
 
4 
36 
Total 174 99 49 
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Table 4 List of grouped variables with abbreviated names, descriptions and measurement units. 
Grouping is indicated by the headers in the first column. The Grace column indicates 
whether the same variable was measured in the GRACE project which consisted of 3 
months studies. Variables given in red are not statistically analysed (see companion 
reports for details). The months 24p for Organ weights denote the animals that died 
prematurely, i.e. before the end of the trial. 
Weights Description Unit Months Grace 
Weight  Body weight at weeks 0, 1 … 13 g/animal 1-3 X 
 Body weight at weeks 15,17… 27 g/animal 4-6 - 
 Body weight at weeks 29, 31 … 52, 53 g/animal 7-12 - 
 Body weight at weeks 55, 57 … 103, 104 g/animal 13-24 - 
Feed  Feed intake in weeks 1, 2 … 13 g/cage 1-3 X 
 Feed intake in weeks 15,17… 27 g/cage 4-6 - 
 Feed intake in weeks 29, 31 … 52, 53 g/cage 7-12 - 
 Feed intake in weeks 55, 57 … 103, 104 g/cage 13-24 - 
BodyWeight Body weight at week 13 g/animal 3 X 
 Body weight at week 27 g/animal 6 - 
 Body weight at week 52 g/animal 12 - 
 Body weight at week 104 g/animal 24 - 
growthRate Growth rate fitted to the weights over weeks 0-13  1/week 3 X 
 Growth rate fitted to the weights over weeks 14-27 1/week 6 - 
 Growth rate fitted to the weights over weeks 27-52 1/week 12 - 
FeedMean Mean of feed intake over period g/an./day 3,6,12,24 X 
Haematology Description Unit Months Grace 
WBC white blood cells 109/L 3,6,12,24 X 
RBC red blood cells 1012/L 3,6,12,24 X 
HGB haemoglobin g/dL 3,6,12,24 X 
HCT haematocrit % 3,6,12,24 X 
MCV mean cell volume fL 3,6,12,24 X 
MCH mean corpuscular haemoglobin pg 3,6,12,24 X 
MCHC mean corpuscular haemoglobin concentration g/dL 3,6,12,24 X 
PLT platelets 109/L 3,6,12,24 X 
LYMR  relative lymphocytes count % 3,6,12,24 - 
LYMA absolute count of lymphocytes 103/uL 3,6,12,24 X 
diffWBC Description Unit Months Grace 
Lymphocytes Percentage of lymphocyte cells in 200 cells % 6 X 
Neutrophils Percentage of neutrophil cells in 200 cells % 6 X 
Monocytes Percentage of monocyte cells in 200 cells % 6 X 
Eosinophils Percentage of eosinophil cells in 200 cells % 6 X 
ClinChem Description Unit  Grace 
ALP alkaline phosphatase μkat/L 3,6,12,24 X 
ALT alanine aminotransferase μkat/L 3,6,12,24 X 
AST aspartate aminotransferase μkat/L 3,6,12,24 X 
BIL bilirubin μmol/L 3,6,12,24 - 
ALB albumin g/L 3,6,12,24 X 
TP total protein g/L 3,6,12,24 X 
Glu glucose mmol/L 3,6,12,24 X 
CHOL cholesterol mmol/L 3,6,12,24 X 
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TAG triglycerides mmol/L 3,6,12,24 X 
Crea creatinine mmol/L 3,6,12,24 X 
Urea urea mmol/L 3,6,12,24 X 
cHGB haemoglobin mg/dL 3,6,12,24 - 
Ca calcium mmol/L 3,6,12,24 X 
Cl chloride mmol/L 3,6,12,24 X 
K potassium mmol/L 3,6,12,24 X 
Na sodium mmol/L 3,6,12,24 X 
P phosphorus mmol/L 3,6,12,24 X 
Urine Description Unit Months Grace 
uVol Urine Volume ml 3,6,12,24 - 
uVolW Urine Volume / bodyweight ml /100g 3,6,12,24 - 
uColour Urine Colour (1-light yellow; 2-yellow; 3-dark yellow) - 3,6,12,24 - 
uBil bilirubin μmol/L  3,6,12,24 - 
uLeu leukocytes leu/uL 3,6,12,24 - 
uNit nitrites neg/pos 3,6,12,24 - 
uOsmoll osmolality mOsm 3,6,12,24 - 
uProtein total protein g/L  3,6,12,24 - 
uGlu glucose mmol/L  3,6,12,24 - 
uHemogl haemoglobin ery/uL 3,6,12,24 - 
uKeton ketone mmol/L 3,6,12,24 - 
upH pH -  3,6,12,24 - 
uUrobili urobilinogen μmol/L  3,6,12,24 - 
Organs Description; all as percentage of BodyWeight Unit Months Grace 
Kidney  Percentage weight of kidney % 12, 24p X 
Spleen Percentage weight of spleen % 12, 24p X 
Liver Percentage weight of liver % 12, 24p X 
AdrenGl Percentage weight of adrenal gland % 12, 24p X 
Heart Percentage weight of heart % 12, 24p X 
Testis Percentage weight of testis (males) % 12, 24p X 
Epididymis Percentage weight of epididymis (males) % 12, 24p X 
Uterus Percentage weight of uterus (females) % 12, 24p X 
Ovary Percentage weight of ovary (females) % 12, 24p X 
Brain Percentage weight of brain % 12, 24p X 
 
All variables that are also observed in the GRACE study are statistically analysed. Some of the other 
variables are not statistically analysed e.g. because all the observed values are (almost) identical; see 
the companion reports for details. All variables except times of death were transformed to the 
natural logarithmic scale and then averaged to the cage level. This implies that, rather than looking at 
differences between feeding group means, ratios between the GM feeds and the Control feed are of 
interest. Only pH as measured in urine was not log transformed because the pH is already measured 
on the log scale. 
2.2 Reference data in GRACE studies 
Data from the GRACE project were used as historic data to set equivalence limits. These data have 
been analysed before as part of the GRACE project (Schmidt and Schmidtke 2014, Schmidt et al. 
2015ab, 2016, 2017, Zeljenková et al. 2014, 2016). Note that in GRACE a completely randomized 
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design, i.e. without blocking, was used. The GRACE data were retrieved from the Cadima website 
(https://www.cadima.info) at 29-11-2016. In GRACE four 90-day studies and one 1-year study, were 
conducted with several control (or reference) feeds as given in Table 5, see Schmidt et al (2017).  
Table 5 Feeds which were used in the five GRACE studies with reference feeds in bold. 
GRACE Study Control 11% GMO 33% GMO 33% Conv-1 33% Conv-2 
A DKC6666 DKC6667-YG-11 DKC6667-YG-33 PR33W82 SY-NEPAL 
B PR32T16 PR33D48-11 PR33D48-33 PR32T83 DKC6815 
C DKC6666 DKC6667-YG-11 DKC6667-YG-33 - SY-NEPAL 
D DKC6666 DKC6667-YG-11 DKC6667-YG-33 - - 
E PR32T16 PR33D48-11 PR33D48-33 - - 
 
In studies D and E only a single reference feed was used and, since the equivalence analysis corrects 
for differences between studies, these studies do not contribute to the between reference variation. 
In studies A, B and C, the reference feeds DKC6666 and SY-NEPAL were replicated. The degrees of 
freedom associated with the between reference feeds variance therefore equals 4. The degrees of 
freedom associated with the residual (between cages) variance varies between 50 and 78 since not 
all measurements were done on all rats in every study.  
We re-analysed the 90-days (3-months) GRACE data from all five studies to enable a comparison with 
the G-TwYST data. This re-analysis is different from the analysis in the GRACE reports in the following 
ways: 
• For the re-analysis all variables were transformed to the natural logarithmic scale and then 
averaged to the cage level; the thus obtained cage means were used in the statistical analysis; 
• the exponential growth model (see section 3.1) was fitted to the weights observed in GRACE to 
obtain an estimate of the growth rate 𝛾𝛾; 
• The sum of the weights of organ pairs was analysed rather than the left and right organs; 
• outliers were identified by applying Grubbs’ outlier test at the 1% level on residuals of a 
one-way ANOVA which is conducted separately for each study. These outliers were set to 
missing. 
Details of the re-analysis are given in the report on Study B (Goedhart % van der Voet, 2017). In Table 
4 it is indicated which G-TwYST variables have also been measured in the GRACE studies. 
3 Data pre-processing 
The initial data pre-processing is described in the companion reports (Goedhart & van der Voet 
2018abcd). 
3.1 Growth curves and feed intake 
For each individual rat growth curves were fitted to the observed weights for restricted periods of 
time. For the data up to 13 weeks (3 months) an exponential growth curve 𝐴𝐴 + 𝐵𝐵 𝑅𝑅𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊 was fitted. A 
re-parameterization of this curve is given by 𝐴𝐴 + 𝐵𝐵 exp(−𝛾𝛾 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊) with the growth rate 𝛾𝛾 defined by 
𝛾𝛾 = − log(𝑅𝑅). For the data between weeks 13 and 27 (6 months), and separately for the data 
between weeks 27 and 52 (12 months), a simple linear regression, 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 = 𝛼𝛼 + 𝛽𝛽 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊, was 
G-TwYST Study A  Main statistical report 
10 
 
fitted to the observed weights, and the growthRate was defined as 𝛾𝛾 = log(𝛽𝛽). In general the growth 
curves fit very well and it was therefore decided to only analyse the final weight observed after week 
13, 27 and 52, further called Weight_13, Weight_27, Weight_52, and the estimated growth rates 𝛾𝛾, 
further called growthRate. No general growth curves could be fitted for the data between weeks 53 
and 104 (24 months), and therefore only the final weights for those animals that survived for 24 
months, further called Weight_104, were statistically analysed. 
The mean weight for each feeding group is given in Figure 1, while the mean weight gain per day per 
animal in each week is given in Figure 2. The mean feed consumption for each feeding group is given 
in Figure 3.  
3.2 Outliers and checking of ANOVA assumptions 
The process for finding potential outliers is described in detail in each of the specific reports. Outlier 
detection was done before the feeding group codes were unblinded. Essentially, Grubbs’ outlier test 
at the 1% level was sequentially applied to the residuals after an analysis of variance on cage means 
for the 3/6/12 month data, and on individual animal data for those animals that survived after 24 
months. This resulted in a number of outliers which were first presented to the study director and 
then to the G-TwYST coordinator. Outliers were classified as either (1) typos or physiologically 
improbable values or (2) values that might be realistic. For the first category the values were set to 
missing, effectively removing the outlier completely. For the second category a statistical analysis 
without and with these outlier was performed.  
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Figure 1 Mean body weights (g) versus week for each feeding group for male rats (top) and for 
female rats (bottom). 
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Figure 2 Mean body weights gain (g/day/animal) versus week for each feeding group for male 
rats (top) and for female rats (bottom). 
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Figure 3 Mean feed consumption (g/day/animal) versus week for each feeding group for male 
rats (top) and for female rats (bottom). 
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4 Statistical methods 
4.1 Analysis of survival curves 
4.1.1 Method 
Survival analysis was performed at the individual level, which disregards the fact that two animals 
were housed in the same cage, and at the cage level with ‘survival of a cage’ defined as survival of 
both animals in the cage. Kaplan-Meier estimates of the survival curves were plotted for all 
animals/cages of a single sex for the five dose groups. The differences between the five dose groups 
were assessed using four overall tests for equality of survival curves (log-rank, Wilcoxon-Breslow, 
Tarone-Ware and Wilcoxon-Peto-Prentice), as defined in Collett (1994).  
Pairwise differences between the control non-GM group and each of the four test dose groups were 
assessed by means of the proportional odds model (Cox, 1972), with a single survival function and 
with blocks and dose groups as treatment factors. Based on the latter model pairwise differences of 
the four test (NK603) groups w.r.t. the control group were assessed using a normal approximation of 
the logarithms of the hazard ratio. In more detail, if 𝑏𝑏 and 𝑠𝑠 represent the estimate of the hazard 
logratio and its standard deviation, then 𝑏𝑏𝐿𝐿 = 𝑏𝑏 − 𝑧𝑧1−𝛼𝛼𝑠𝑠 and 𝑏𝑏𝑈𝑈 = 𝑏𝑏 + 𝑧𝑧1−𝛼𝛼𝑠𝑠 are one-sided lower 
and upper 1 − 𝛼𝛼 confidence limits for the true hazard logratio. Note that equal hazards correspond 
to a value 0 in the logratio scale. Therefore we find a significant increase in hazard if 𝑏𝑏𝐿𝐿 > 0. A one-
sided P-value can be calculated based on the normal distribution. 
The proportional hazards model was also fitted using a factorial representation of the dose groups. 
The structure of the G-TwYST study is a 2 by 2 factorial design for the GM feeding groups with factors 
GM inclusion rate (IR, 11% or 33%) and use of Roundup (RU, -  or +), with an added control for the 
non-GM control group. This structure allows a more sensitive analysis, integrating over the five dose 
group, according to the model for the hazard logratio: 
𝑃𝑃𝑃𝑃𝑖𝑖𝑖𝑖 = 𝜇𝜇 + 𝐺𝐺𝐺𝐺 + 𝐼𝐼𝑅𝑅𝑖𝑖 + 𝑅𝑅𝑈𝑈𝑖𝑖 + 𝑊𝑊𝑖𝑖𝑡𝑡𝑖𝑖𝑖𝑖  for GM groups, 𝑊𝑊 = 1,2; 𝑗𝑗 = 1,2. 
In this model the fixed term 𝐺𝐺𝐺𝐺 models the difference between the four GM groups (averaged) and 
the control. This term is only interpretable if the other three fixed terms can be assumed to be zero. 
The main effect 𝐼𝐼𝑅𝑅2 − 𝐼𝐼𝑅𝑅1 models the difference between the groups with GM inclusion rates 33% 
and 11%, and similarly, the main effect 𝑅𝑅𝑈𝑈2 − 𝑅𝑅𝑈𝑈1 models the difference between the groups with 
and without Roundup. These main effects are only useful when there is no interaction 𝑊𝑊𝑖𝑖𝑗𝑗𝑖𝑖𝑖𝑖 between 
GM inclusion rate and Roundup. 
These survival analyses were performed using procedures KAPLANMEIER, RSTEST, RPROPORTIONAL 
and RPHFIT, and direct programming in GenStat 18 (VSN International, 2015). 
4.1.2 Results 
This section summarises the main findings reported in the companion report (Goedhart & van der 
Voet 2018d). 
Kaplan-Meier estimates of the survival curves per sex and per feeding group based on individual rats, 
and based on cages, are given in Figure 4. The event for a cage was defined as the day at which the 
first animal died. This definition respects the fact that cage is the experimental unit. 
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Figure 4 Kaplan-Meier estimates of the survival curves for all 350 rats per sex (left figures), and 
for cages (right figures) where the event per cage is the day of death of the first animal.  
Four overall tests, testing the overall null hypothesis that the survival curves are identical, were 
performed. According to these tests, which do not account for differences between blocks, there 
were no overall significant differences between the survival curves at the 5% level.  
On a more detailed level, employing the proportional odds model, the one-sided null hypothesis was 
tested that the hazard ratio of each of the four GM feeding groups relative to the control non-GM 
group was equal to or smaller than one. The hazard ratios relative to the control non-GM group are 
graphically depicted in Figure 5. The null hypothesis was never rejected. 
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Figure 5 Hazard ratios according to the proportional hazards model relative to the hazard of the 
control non-GM feeding group. 90% confidence intervals for hazard ratios are indicated 
by error bars; when the lower limit is larger than 1 the one-sided null hypothesis is 
rejected. The hazard ratio is also given at the bottom of each bar. 
In addition, a factorial analysis has been performed employing chi-squared likelihood ratio testing in 
the proportional odds model. Factorial effects are graphically depicted in Figure 6. In 16 tests, there 
was one P-value (just) below 0.05. There is an indication that there might be an effect of Roundup in 
males (P-values equal to 0.053 and 0.037 in the analysis at the animal and cage level, respectively).  
The ratio of the hazard for Roundup GM feeds versus non-Roundup GM feeds is estimated by 1.52 
for male animals and 1.73 for male cages. This indicates that the non-Roundup GM feeds have a 
better survival rate. There is also an indication that in females the GM feeds could have a better 
survival rate than the non-GM control feed (P-values equal to 0.053 and 0.065 in the analysis at the 
animal and cage level, respectively). The estimated hazard ratio for the GM feeds versus the control 
feed equals 0.62 for female animals and 0.58 for female cages. 
G-TwYST Study A  Main statistical report 
17 
 
 
Figure 6 Mean hazard ratios for the overall GM versus non-GM control (red bars), for the 11% 
and 33% GM inclusion rates (green bars), and for the GM feeds without Roundup (RU-) 
and with Roundup (RU+, blue bars). 
4.2 Analysis of mortality at 24 months 
4.2.1 Method 
Whereas survival analysis considers the mortality pattern over the time, a more restricted analysis 
can be done on the mortality rates at specific points in time. In such analyses the exact time of death 
of dead animals is not considered. Death events of animals were rare up to month 12, with at most 3 
dead animals per group of 50 (Table 6,).  Therefore only the mortality rates at 24 months were 
statistically analysed.  
In this analysis only the 50 animals per sex and feeding group that were part of the 2-year cohort 
were statistically analysed. Fitting a beta-binomial regression model (Williams, 1982), by means of 
maximum likelihood, to the number of dead animals in each cage as response variable revealed that 
the estimate of the over-dispersion parameter 𝜙𝜙 equals its bounded value of 0.0001 (males and 
females). This indicates that there was no over-dispersion and therefore the ordinary logistic model 
(McCullagh and Nelder, 1989) was used to analyse the number of dead animals per cage. After 
allowing for differences between blocks one-sided pairwise Wald tests were performed with null 
hypothesis that the mortality probability of a GM feed is equal to or smaller than the mortality 
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probability of the non-GM control feed. The logistic model was also fitted using a factorial 
representation of the dose groups. 
 
Table 6 Mortality of males and females after 3, 6, 12 and 24 months. Mortality of a cage is 
defined as mortality of the fist animal in the cage. 
Feed 
Male animals (50 total) Male cages (25 total) 
3m 6m 12m 24m 3m 6m 12m 24m 
Control - - - 18 - - - 14 
NK11- - - 2 14 - - 2 12 
NK33- - - 1 17 - - 1 14 
NK11+ - 1 2 18 - 1 2 16 
NK33+ - - 2 27 - - 2 21 
Feed 
Female animals (50 total) Female cages (25 total) 
3m 6m 12m 24m 3m 6m 12m 24m 
Control - 1 3 24 - 1 3 17 
NK11- 1 1 3 26 1 1 3 18 
NK33- - - 2 20 - - 2 15 
NK11+ - - 1 10 - - 1 16 
NK33+ - - - 17 - - - 14 
 
4.2.2 Results 
This section summarises the main findings reported in the companion report (Goedhart & van der 
Voet 2018d). Mortality rates after 24 months are shown in Figure 7. The average mortality at 24 
months was 38% for male animals and 39% for female animals. At the level of the experimental unit 
(cage) the average mortality at 24 months was 62% for males and 64% for females. 
Using the logistic model and one-sided testing, there was one significant result (P<0.05) in 8 tests 
(males and females, 4 comparisons with the Control group). There was an indication (P=0.029) that 
the mortality rate for NK33+ in males (54%) is larger than for the control non-GM feed (36%). 
The factorial analysis, employing chi-squared likelihood ratio testing in the logistic regression model, 
found one significant result (P<0.05) in 8 tests. There was no indication for an overall higher mortality 
rate in the GM groups (P=0.78 for males, and P=0.35 for females). However, there was an indication 
for a Roundup effect in males (P=0.030). Keeping in mind that the mortality in the male Control 
group was 36%, the mean percentages dead were 31% for NK603 without RoundUp and 45% for 
NK603 with RoundUp.  
 
G-TwYST Study A  Main statistical report 
19 
 
 
Figure 7 Percentage dead animals after 24 month in the 2-year cohort. 90% confidence intervals 
for the percentage are indicated by error bars. The percentage is also given at bottom of 
each bar. 
4.3 Equivalence testing using historical data 
4.3.1 Method 
Equivalence testing was introduced for GM safety assessment for compositional data in the EFSA 
guidance for risk assessment of food and feed from GM plants (EFSA 2011a). In the context of 90-day 
studies in rodents, EFSA (2014) recognized the potential advantages of equivalence testing and 
recommended further investigation. In response to this, an equivalence test was developed in the 
G-TwYST project. This test compares the difference between a test (T) and a control (C) feed, 
obtained simultaneously in a current study, to the typical differences between reference (R) varieties 
obtained in one or more historical studies (van der Voet et al., 2017). The equivalence test is 
corrected for between-study differences, and the within-study variation between references R is 
used to set equivalence limits for the difference between T and C in the current study. The so-called 
Distribution Wise Equivalence (DWE) criterion is used in this test. An equivalence limit for the current 
study is set using the concept of desired power in a simplified situation, where there is no between-
reference variation, where the historical and current studies have the same residual variance, and 
where the current study is assumed to have a sample size as approved by a regulator. The method is 
fully described in van der Voet et al. (2017) .  
The equivalence test of van der Voet et al. (2017) requires historic data sets for the endpoints of 
interest. For the 3 months data in study A the GRACE reference data described in section 2.2 serve 
this purpose. For the data obtained after 6, 12 and 24 months no corresponding reference data were 
available. If variance components between and within reference feeds would be stable over time, the 
3-months GRACE data could still be used.    
Where possible, employing the historic GRACE studies, some statistics are calculated from the 
historic data: the within-study between reference feeds sums of squares (𝑆𝑆𝑆𝑆𝑅𝑅), the residual sums of 
squares (𝑆𝑆𝑆𝑆𝐸𝐸) and their associated degrees of freedom 𝑑𝑑𝑓𝑓𝑅𝑅 and 𝑑𝑑𝑓𝑓𝐸𝐸. It also involves the effective unit 
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replication 𝑖𝑖𝑊𝑊𝑒𝑒𝑒𝑒 which is necessary to estimate the between reference variance employing the mean 
squares for feeds and for residuals. The required values based on the five GRACE studies A-E are 
given in Appendix 2. 
The test also requires, for the current G-TwYST study, estimates of differences between the GMO 
feeds and the control feed, as well as the residual sums of squares and the associated degrees of 
freedom resulting from an analysis of variance. These are given in the companion reports (Goedhart 
% van der Voet 2018abcd).  
The equivalence limit 𝜃𝜃0 for the DWE criterion is only based on the design values of the historical 
studies and on three regulatory values: the minimal regulatory sample size 𝑖𝑖0, a probability 𝛼𝛼 which 
defines a 100(1 − 𝛼𝛼)% two-sided confidence interval for the difference in the current study, and a 
probability 𝛽𝛽 which defines the desired power 1 − 𝛽𝛽 for the equivalence test. The regulatory sample 
size 𝑖𝑖0 was set to the level of replication in G-TwYST study A, which is different for different variable 
groups. Values 𝛼𝛼 = 0.05 and 𝛽𝛽 = 0.05 resulting in a power of 0.95. Furthermore the equivalence 
limit 𝜃𝜃0 is calculated by simulating a large number of datasets in a simplified situation, where for 
each datasets an upper 100(1 − 𝛼𝛼)% percentile, 𝜃𝜃𝑢𝑢𝑢𝑢𝑢𝑢0 , for the DWE criterion is approximated by a 
large number of so-called GPQ samples. We simulated 40,000 datasets with 15,000 GPQ samples for 
each dataset. Note that 𝜃𝜃0 is calculated as the upper 100(1 − 𝛽𝛽)% percentile of the thus obtained 
40.000 values of 𝜃𝜃𝑢𝑢𝑢𝑢𝑢𝑢0 . The DWE criterion for the current dataset was approximated by means of 
100,000 GPQ samples. Note that the equivalence limit 𝜃𝜃0 is calculated assuming a regulatory sample 
size 𝑖𝑖0 which implies 2(𝑖𝑖0 − 1) degrees of freedom for error in the current study. The current 
G-TwYST study has more degrees of freedom for error, see Table 3. 
The DWE equivalence test results in a DWE interval as a so-called equivalence limit scaled difference 
(ELSD), which can be used both for difference and for equivalence testing. The hypothesis of no 
difference is rejected in case the interval does not contain zero, while the non-equivalence 
hypothesis is rejected when the interval fully lies inside the interval (-1,1). In the companion reports 
(Goedhart % van der Voet 2018abcd) the confidence intervals are also presented at the original ratio 
scale, with inclusion of the estimated equivalence limits (red bars) and their uncertainty (blue bars). 
Note that the latter graphs cannot be used directly for performing the equivalence test. However, 
they show the effects and equivalence limits at a more familiar scale. 
4.3.2 Results 
This section summarises the main findings reported in the companion reports (Goedhart & van der 
Voet 2018abcd). 
The residual variances for 3, 6, 12 and 24 months data are shown in Figure 8, expressed as a 
percentage of the corresponding residual variance in the historical GRACE data. From these graphs it 
is clear, that the variances at month 3 and month 6 are similar, such that the historical 3-months 
GRACE data can also serve as reference data for equivalence tests with 6 months data. However, at 
month 12 many variances are much higher, and such use becomes doubtful. At month 24, most 
variances have become much larger. The conclusion is that the use of the 3-months GRACE data as a 
historical reference for equivalence testing in G-TwyST should be restricted to the 3 months and 6 
months data. 
G-TwYST Study A  Main statistical report 
21 
 
 
Figure 8 Residual variance for 4 points in time, expressed as a percentage of the historical 
reference residual variance. The red points are for the diffWBC measurements, which 
were only observed after 6  months, while the blue points are for the organ weights 
which were only observed after 12 months. 
Equivalence tests were performed given tentative settings for regulatory parameters, 𝛼𝛼 = 0.05, 𝛽𝛽 =0.05 and 𝑖𝑖0 equal to the sample sizes in the current study, i.e. 35 for the weight variables and 20 for 
haematology, differential white blood cell counts and clinical biochemistry.  The results are shown in 
Figure 9 - Figure 12, and summarised in Table 7. 
The performance of the equivalence test was dependent on the ratio of the residual variance in the 
current study to the residual variance in the historical study. Combined over all 412 equivalence tests 
with a variance ratio (VR) of at most 1.5, equivalence was established in 411 cases (99.8%).  However, 
for the 44 tests with VR > 1.5, this was possible in only 12 cases (27%). In Table 7 it is also shown that 
in 455 of all 456 tests the point estimate was inside the equivalence limits, and therefore equivalence 
was more likely than not according to the definition of EFSA (2011). Again, the exception was for one 
of the VR > 1.5 cases. 
Obviously, large residual variances in the current study relative to the reference data are 
problematic. Analysing these situations might lead to different conclusions. On the one hand, if the 
problem is seen as a too low precision obtained in the current study, then the quality of the current 
study for this variable is sub-standard, and it is just appropriate that this type of equivalence testing 
fails to prove equivalence. Alternatively, if the high variance ratios are considered to be the result of 
accidentally very small variation in the reference data, then the lesson would be to improve the 
reference data collection. 
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Table 7 Summary of equivalence tests employing historical data. 𝑽𝑽𝑽𝑽 denotes the ratio of the 
residual variance in the current study and the residual variance in the historic GRACE 
studies. 
3 months 
Male rats Female rats 
VR ≤ 1.5 VR > 1.5 VR ≤ 1.5 VR > 1.5 
#tests 100 8 96 12 
#equivalence 100 4 
failed 
MCV 4x 
95 
failed:  
MCHC 1x 
4 
failed: 
growthRate 4x 
CHOL 3x 
P 1x 
#equivalence more 
likely than not 
100 8 96 12 
6 months 
Male rats Female rats 
VR ≤ 1.5 VR > 1.5 VR ≤ 1.5 VR > 1.5 
#tests 108 12 108 12 
#equivalence 108 2 
failed:  
MCV 2x 
MCH 4x 
Lymphocytes 4x 
108 2 
failed:  
MCHC 2x 
Monocytes 4x 
CHOL 4x 
#equivalence more 
likely than not 
108 12 108 11 
failed: 
Monocytes 1x 
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Figure 9 Equivalence testing at 3 months of GM feeding groups versus the non-GM control feed for males. For estimates (square symbols) on the left of 
zero the GM feed has a smaller mean than the control feed. Endpoints labelled with a golden background have a large residual variance 
compared to the historical studies (VR>150%). Fuchsia coloured symbols denote a significant difference.  
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Figure 10 Equivalence testing at 3 months of GM feeding groups versus the non-GM control feed for females. For estimates (square symbols) on the left 
of zero the GM feed has a smaller mean than the control feed. Endpoints labelled with a golden background have a large residual variance 
compared to the historical studies (VR>150%). Fuchsia coloured symbols denote a significant difference.  
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Figure 11 Equivalence testing at 6 months of GM feeding groups versus the non-GM control feed for males. For estimates (square symbols) on the left of 
zero the GM feed has a smaller mean than the control feed. Endpoints labelled with a golden background have a large residual variance 
compared to the historical studies (VR>150%). Fuchsia coloured symbols denote a significant difference.  
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Figure 12 Equivalence testing at 6 months of GM feeding groups versus the non-GM control feed for females. For estimates (square symbols) on the left 
of zero the GM feed has a smaller mean than the control feed. Endpoints labelled with a golden background have a large residual variance 
compared to the historical studies (VR>150%). Fuchsia coloured symbols denote a significant difference.
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4.4 Equivalence testing using target effect sizes 
4.4.1 Method 
For a limited number of variables Hong et al (2017) use what they call targeted effect sizes for the 
purpose of statistical power analysis for a rat sub-chronic feeding study. Although they warn that 
these effect sizes should not be considered synonymous with biologically or toxicologically relevant 
effects, these targeted effect sizes were used for equivalence testing. The targeted effect sizes for 
nine variables that are also relevant in G-TwYST are given in Table 8, along with the implied limits on 
the log-ratio scale which are used in the equivalence test. Note the asymmetry in these limits: for a 
targeted effect size of +/- 30%, +30% corresponds to a factor 1.3 which is 0.262 on the log scale, 
while -30% corresponds to a factor 0.7 which equals -0.357 on the log scale. 
Table 8 Targeted effect sizes from Table 1 in Hong et al (2017) along with their implied lower 
and upper limits on the ratio scale and on the log-ratio scale. 
Name in Hong et al (2017) G-TwYST 
Name 
Targeted 
effect size 
Ratio scale Log-ratio scale 
Lower Upper Lower Upper 
Body weight; final non-fasted BodyWeight -  10% 0.90 - -0.105 - 
Leukocyte (WBC) count WBC +/-  30% 0.70 1.30 -0.357 0.262 
Lymphocyte (ALYM) count LYMA +/-  30% 0.70 1.30 -0.357 0.262 
Alkaline phosphatase (ALKP) ALP +  100% - 2.00 - 0.693 
Creatinine (CREA) Crea +  50% - 1.50 - 0.405 
Blood urea nitrogen (BUN) Urea +  50% - 1.50 - 0.405 
Cholesterol (CHOL)  CHOL +  200% - 3.00 - 1.099 
Kidney, % body weight Kidney +  25% - 1.25 - 0.223 
Liver, % body weight Liver +  25% - 1.25 - 0.223 
 
Denoting the limits on the log-ratio scale as 𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 and 𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢, the two-sided non-equivalence null 
hypothesis reads, with Δ the ratio of the mean of a GMO feed and the mean of the control feed: 
 𝑃𝑃0: log(𝛥𝛥) <  𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 or log(𝛥𝛥) >  𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢  
 𝑃𝑃1:  𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 ≤  log(𝛥𝛥) ≤  𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢 
This was tested by means of the TOST approach of Schuirmann (1987) at the 5% level which is 
equivalent to checking whether the 10% confidence interval for log(𝛥𝛥) lies completely within the 
interval �𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 ,𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢� composed of the equivalence limits. For one-sided tests the same confidence 
interval can be used where only one of the confidence bounds is relevant.  
4.4.2 Results 
This section summarises the main findings reported in the companion reports (Goedhart & van der 
Voet 2018abcd). 
90% confidence intervals for 7 variables, with equivalence limits according to the targeted effect 
sizes in Hong et al. (2017), are given in Figure 13 - Figure 16 for 3, 6, 12 and 24 months data, each for 
males and females. Note that these are 90% intervals. The results of the equivalence tests are 
summarised in Table 9. Equivalence is easily demonstrated for the 3, 6 and 12 months data, but again 
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the large residual variance of the 24 months data is responsible for 13 cases where equivalence could 
not be proven. 
Table 9 Summary of equivalence tests with fixed target effect sizes. 
 Males Females 
3m 6m 12m 24m 3m 6m 12m 24m 
Number of tests 28 28 36 28 28 28 36 28 
Number of tests showing equivalence 28 28 36 22a 28 28 36 21b 
Number of tests showing equivalence  
more likely than not 
28 28 36 28 28 28 36 28 
 a failures for Weight_104 (1x), WBC (1x), LYMA (4x);   b failures for Weight_104 (3x), WBC (3x), LYMA (1x) 
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Figure 13 3 months data, 90% confidence intervals for the ratio of the mean of the GMO feed and the control feed for selected variables for males (left) 
and females (right), along with equivalence intervals defined by targeted effect sizes of Hong et al. (2017). 
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Figure 14 6 months data, 90% confidence intervals for the ratio of the mean of the GMO feed and the control feed for selected variables for males (left) 
and females (right), along with equivalence intervals defined by targeted effect sizes of Hong et al. (2017). 
G-TwYST Study A  Main statistical report 
31 
 
  
Figure 15 12 months data, 90% confidence intervals for the ratio of the mean of the GMO feed and the control feed for selected variables for males (left) 
and females (right), along with equivalence intervals defined by targeted effect sizes of Hong et al. (2017). 
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Figure 16 24 months data, 90% confidence intervals for the ratio of the mean of the GMO feed and the control feed for selected variables for males (left) 
and females (right) that survived for 24 months, along with equivalence intervals defined by targeted effect sizes of Hong et al. (2017).
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4.5 Classical statistical analysis 
4.5.1 Method 
G-TwYST study A is based on OECD guidance 453 on combined chronic toxicity and carcinogenicity 
studies (OECD 2009), EFSA guidance complementing the OECD guidance for whole food/feed studies 
(EFSA 2011b), and additional EFSA clarifications (EFSA 2013, 2014). OECD guidance 453 (OECD 2009) 
requires numerical results to be evaluated by an appropriate and acceptable statistical method, but 
gives no further guidance on statistical analysis. More detailed guidance, although strictly meant for 
chronic and carcinogenicity studies, is provided in chapter 4 of OECD guidance document 116 (OECD 
2012), which describes a flowchart for statistical analysis methods (reproduced in Figure 17).  
 
Figure 17 Classical approach to statistical analysis of data in long-term toxicity studies (copied 
from OECD 2012). 
EFSA (2011b) gives further guidance, such as considering cage as the experimental unit, and including 
block in the model for data from a randomised block design (as is the case for the G-TwYST study). 
We applied classical statistical methods for continuous data in line with these OECD and EFSA 
approaches, and very similar to the approaches followed in the GRACE project (Schmidt and 
Schmidtke 2014, Schmidt et al 2015ab). 
A classical analysis of variance was performed on the cage means after log transforming the data. 
This was done in the statistical program R. The R-script which analyses a single response variable is 
given in Appendix 3. The classical analysis involves: 
• Analysis of variance according to the randomized block design employing the model “Block + 
Treatment” where Treatment defines the five feeding groups. The model was fitted by means of 
linear regression, using the lm() function in R, because this takes proper account of any missing 
values. The usual summary statistics are saved as well as estimates for the difference between 
GMO feeds and the control and corresponding standard errors, t-values and p-values. These are 
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all calculated using the pooled ANOVA residual standard error which generally has 28 degrees of 
freedom. 
• The ANOVA p-values do not take account of multiple comparisons between the feeds. Therefore 
Dunnett’s test was performed, which also compares the GMO feeds with the control feed, 
taking account of the number of comparisons made. Dunnett’s test is performed by means of 
the glht() function in the multcomp R-package. 
• The residuals of the analysis of variance are checked for normality using the Kolmogorov-
Smirnov test as well as the Shapiro-Wilk test for normality. These tests are only approximate 
since the residuals are not independent. The p-value of the Kolmogorov-Smirnov test is not 
reported since it is almost always larger that the p-value of the Shapiro-Wilk test, moreover for 
variables where it is smaller the p-value is far from significant. 
• Note that the ANOVA residuals were already assessed by means of a normal probability plot and 
a plot of residuals versus fitted values (see companion reports). 
• The non-parametric Wilcoxon signed rank test is used to test for a difference between each 
GMO feed and the control feed. Note that this test only uses data of these two feeds and that 
the test employs the within block difference between the GMO feed and the control feed. The 
p-value of the test is calculated by means of the wilcox.test() function in R which calculates exact 
probabilities. 
• Homogeneity of variance is assessed by means of Bartlett’s test and by means of Levene’s test 
both using the mean and the median. These test do not take blocking into account and basically 
compare the within feed variances. Note that homogeneity of variance was already assessed by 
means of a plot of residuals versus fitted values (see  companion reports). The p-value of the 
Levene test with the median is not reported since it is almost always larger that the p-value of 
the Levene test with the mean, and for variables where it is smaller the p-value is far from 
significant. Note that both analysis of variance and non-parametric tests require homogeneity of 
variance. 
• Finally, for each feeding group separately, normality was assessed by means of the Kolmogorov-
Smirnov test and the Shapiro-Wilk test. The p-value of the Kolmogorov-Smirnov test is always 
larger than 5% and is thus not reported. 
4.5.2 Results 
This section summarises the main findings reported in the companion reports (Goedhart & van der 
Voet 2018abcd). Hypotheses of equality were tested against two-sided alternatives of difference for 
each of the four GM groups  vs. the non-GM Control group. Across the four time points (3, 6, 12, 24 
months) and all available data, this amounted to 1256 comparisons, using three statistical methods 
(Dunnett’s test, t-test, Wilcoxon test) for a total of 3768 test results. All tests were performed at the 
5% level, so that 0.05 x 3768 = 188 significant results would be in line with the theoretical level of the 
tests under the joint null hypotheses. Table 10 gives an overview of the numbers and frequencies of 
significant results, whereas the full results are reported in 
Table 10 Absolute numbers and relative frequencies of significant results (P<0.05) in classical 
tests comparing GM groups to the non-GM group, combined for males and females. For 
the three individual tests, frequencies significantly higher (P<0.05) than the nominal test 
level of 5% by an exact binomial test are shown with a red background. 
 3 months 6 months 12 months 24 months 
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Number of comparisons 288  320  352  296  
Dunnett 3 (1%) 3 (1%) 10   (3%) 2 (1%) 
t- test 17  (6%) 14 (4%) 38 (11%) 11 (4%) 
Wilcoxon 19  (7%) 14 (4%) 32   (9%) 7 (2%) 
Any of these 26 (9%) 20 (6%) 46 (13%) 14 (5%) 
 
The highest frequency of significant results is observed for the 12 months data, where the t-test finds 
38 significant differences (11%) and Wilcoxon’s test 32 (9%), although Dunnett’s test, which correct 
for the multiplicity of four comparisons per endpoint, finds only 10 significant results (3%).  In 
comparison, the frequencies for the 3, 6 and 24 months data are lower, and not significantly 
different from the nominal test level of 5%. 
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Table 11 Estimated ratios of GM groups versus the non-GM control group for male rats for months 3, 6, 12 and 24. Significant ratios are marked, with 
red background colouring, as follows: D: P<0.01 by Dunnett-test, d: P<0.05 by Dunnett-test, T: P<0.01 by t-test but not by Dunnett-test, 
t: P<0.05 by t-test but not by Dunnett-test, W: P<0.01 by Wilcoxon signed rank test, w: P<0.05 by Wilcoxon signed rank test.  
Weights 
Males 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Weight 0.98  0.98  0.97  1.01  0.99  0.99  0.99  0.98  1.00  0.99  0.99  0.96  1.00  1.00  1.02  0.98  
growthRate 0.99  0.99  0.96  -  1.00  1.00  1.02  -  1.01  0.97  1.01  -  1.00  1.03  1.13 tw -  
FeedMean 1.01  0.98 w 0.96 dTW 0.98  0.99  0.98 w 0.97 w 0.98  1.00  0.99  0.97 tW 0.95 t 1.03 tw 1.02  1.01  1.03  
Haematology 
Males 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
WBC 1.00  0.95  0.94  1.04  1.13 tW 1.18 dTw 1.12  0.93  1.07  1.15 t 1.02  1.07  1.09  1.05  1.08  1.17  
RBC 0.99  1.00  1.00  0.98  1.00  1.00  1.00  1.01  1.00  1.00  1.02  1.00  1.00  1.01  1.01  0.99  
HGB 0.99  1.00  1.01  0.97  1.00  1.01  1.00  1.02  0.99  1.00  1.01  1.00  1.00  1.02  1.01  1.01  
HCT 0.99  1.00  1.00  1.00  1.00  1.01  1.01  1.01  1.00  1.00  1.03 tw 0.99  1.00  1.01  1.01  1.00  
MCV 1.00  1.01  1.00  1.02  1.00  1.01  1.01  1.02  1.00  1.00  1.00  1.01  1.01  1.01  1.01  1.01  
MCH 1.00  1.00  1.00  1.00  1.01  1.01  1.01  1.01  0.99  1.00  0.99  1.00  1.00  1.01  1.00  1.01  
MCHC 1.00  1.00  1.00  0.99  1.00  1.00  1.00  0.99  0.99  1.00  0.99 tw 1.00  1.00  1.01  1.00  1.01  
PLT 1.03  0.97  0.99  1.03  1.05  1.04  1.08 d 1.05  1.05  1.04  1.03  1.05  1.07 w 1.03  1.08 dTW 1.04  
LYMR 0.99  0.98  1.00  1.04  0.98  0.99  1.04  1.05  1.00  1.00  1.02  1.04  1.01  1.01  0.98  0.94  
LYMA 1.00  0.93  0.96  1.09  1.11  1.16 tw 1.16 t 1.08  1.07  1.15 t 1.04  1.15  1.10  1.06  1.03  1.07  
diffWBC 
Males 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Lymphocytes -  1.02  -  -  -  0.99  -  -  -  1.00  -  -  -  1.03  -  -  
Neutrophils -  0.97  -  -  -  1.02  -  -  -  0.97  -  -  -  0.93  -  -  
Monocytes -  0.75 tw -  -  -  0.89  -  -  -  0.78 tw -  -  -  0.87  -  -  
Eosinophils -  0.98  -  -  -  1.28  -  -  -  1.09  -  -  -  1.24  -  -  
ClinChem 
Males 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
ALP 1.01  1.02  1.07  1.04  0.98  0.96  1.03  0.85  0.99  0.98  1.07  0.92  1.02  0.99  1.03  0.76  
ALT 1.01  1.01  1.01  1.03  0.96  1.02  0.98  1.02  0.97  0.98  1.05  1.02  0.97  1.01  1.04  1.05  
AST 1.00  1.03  1.02  1.13  0.97  1.07  0.99  1.05  0.91  1.03  0.94  1.05  0.95  1.01  0.99  1.06  
BIL 1.05  1.03  0.97  1.03  1.05  1.12 t 0.99  1.04  0.94  1.08  0.94  1.01  1.02  1.07 w 1.02  0.95  
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ALB 0.99  1.00  0.99  1.00  0.99  1.01  1.01  1.06  0.98 w 1.00  1.00  1.05  1.00  1.00  0.99  1.01  
TP 1.00  1.00  0.99  1.01  0.99  1.00  1.01  1.02  1.00  1.01  1.00  1.01  1.00  1.00  1.00  1.01  
Glu 0.98  0.97  1.00  1.00  0.98  0.98  0.99  1.02  1.02  1.01  1.05  0.97  1.04  1.04  1.01  0.90  
CHOL 1.02  1.03  1.03  0.93  1.00  1.01  1.03  0.89  0.97  1.00  0.96  0.93  1.01  1.04  1.03  1.05  
TAG 1.09  1.05  1.03  1.26 w 1.10  1.09  1.12  1.08  1.11  1.12 tw 1.18 tw 1.04  1.01  1.06  1.14  1.22  
Crea 0.94  0.97  0.96  1.05  0.95  0.99  0.99  0.96  0.97  1.00  0.97  0.96  0.96  0.96  0.97  1.12  
Urea 0.95  0.97  0.99  1.18 t 0.97  1.00  1.00  1.02  0.97  1.00  1.04  1.06  0.99  0.99  0.98  1.05  
cHGB 1.12  1.16  0.93  1.45 tw 1.07  1.24  1.06  1.13  0.94  1.24  1.03  1.18  1.06  1.10  1.05  1.34  
Ca 1.00  1.00  1.00  1.00  1.00  1.01  1.00  0.99  1.00  1.00  1.00  0.99  1.00  1.00  1.00  1.00  
Cl 1.00  1.00  0.99  1.00  1.00  1.00  0.99 dTW 1.00  0.99  1.00  0.99 tw 1.01  1.01  1.00  0.99 t 1.00  
K 1.02  1.02  1.00  1.03  1.01  1.03  1.02  1.01  1.00  1.05 t 1.00  1.05 tw 1.02  1.01  1.00  1.03  
Na 1.00  1.00  1.00  1.00  1.00  1.00  1.00  1.01 w 1.00  1.00  1.00  1.01  1.00  1.00  1.00  1.00  
P 0.95 tw 0.97  0.94 tW 1.09  0.99  1.01  1.02  0.92  0.97  1.02  0.96  1.00  0.96  0.99  0.95 w 1.07  
Urine 
Males 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
uVol 1.02  1.07  1.00  1.10  0.78 t 0.80 t 0.83 t 0.83  0.94  0.91  0.86 t 1.03  0.95  1.04  0.96  1.00  
uVolW 1.03  1.08  1.01  1.13  0.78  0.81  0.83 t 0.86  0.94  0.92  0.83 t 1.08  0.93  1.03  0.94  1.04  
uLeu 0.95  0.90  0.61  0.98  1.47 t 1.50  1.01  1.03  1.06  1.08  0.60 w 0.73  1.25  0.95  0.58  1.18  
uOsmoll 0.94  0.92  1.01  0.96  1.20  1.21  1.18 t 1.07  1.07  1.10  1.14  0.92  1.02  0.96  1.08  1.04  
uProtein -  -  -  1.06  -  -  -  0.95  -  -  -  0.77  -  -  -  1.38  
uHemogl -  -  -  1.64  -  -  -  1.11  -  -  -  1.13  -  -  -  1.08  
uKeton 1.14  0.92  1.03  1.20  1.79 t 1.21  1.68 dTw 1.29  1.13  0.92  0.79  1.22  1.19  0.76  1.08  1.76 t 
upH 0.84  0.90  0.88  1.07  0.98  0.90  1.05  0.98  0.95  1.03  1.11  1.04  0.86  0.86  0.86  1.18  
Organs 
Males 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Kidney -  -  1.06 w -  -  -  1.06  -  -  -  1.00  -  -  -  1.01  -  
Spleen -  -  1.04  -  -  -  1.09  -  -  -  0.99  -  -  -  1.02  -  
Liver -  -  1.00  -  -  -  1.01  -  -  -  1.00  -  -  -  0.96  -  
AdrenGl -  -  1.07 w -  -  -  1.07  -  -  -  0.94  -  -  -  1.03  -  
Heart -  -  1.04  -  -  -  1.06  -  -  -  1.00  -  -  -  0.99  -  
Testis -  -  1.07  -  -  -  1.02  -  -  -  1.01  -  -  -  1.05  -  
Epididymis -  -  1.12 tw -  -  -  1.03  -  -  -  0.95  -  -  -  1.03  -  
Brain -  -  1.06  -  -  -  1.02  -  -  -  0.97  -  -  -  1.01  -  
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Table 12 Estimated ratios of GM groups versus the non-GM control group for female rats for months 3, 6, 12 and 24. Significant ratios are marked, with 
red background colouring, as follows: D: P<0.01 by Dunnett-test, d: P<0.05 by Dunnett-test, T: P<0.01 by t-test but not by Dunnett-test, 
t: P<0.05 by t-test but not by Dunnett-test, W: P<0.01 by Wilcoxon signed rank test, w: P<0.05 by Wilcoxon signed rank test.  
Weights 
Females 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Weight 0.99  0.99  0.98  0.95  0.99  0.99  1.00  0.93  0.99  0.99  0.99  0.95  0.99  1.00  0.99  0.98  
growthRate 0.99  0.99  0.90  -  0.99  1.00  1.05  -  0.99  0.97  0.99  -  0.99  1.03  0.96  -  
FeedMean 1.03 tw 1.00  0.98  1.00  1.01  1.01  1.01  0.98  1.01  1.01  0.98  0.98  1.04 DW 1.03  1.02  1.02  
Haematology 
Females 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
WBC 1.06  1.04  1.06  1.11  1.03  1.03  0.93  0.99  0.97  0.96  0.97  1.26  1.08  1.03  1.05  1.11  
RBC 1.00  1.00  1.00  1.00  1.01  1.01  1.01  1.01  1.01  1.00  1.03 w 0.98  1.02  1.01  1.02  1.02  
HGB 0.99  0.99  1.00  0.98  1.01  0.99  1.00  0.98  0.99  0.99  1.01  0.99  1.00  1.00  1.01  0.99  
HCT 1.00  1.00  1.01  0.98  1.01  1.00  1.02 w 0.97  1.00  1.00  1.02  0.99  1.01  1.00  1.02  0.99  
MCV 1.00  1.00  1.01  1.01  0.99  0.99  1.00  0.99  0.99  1.00  0.99  1.00  0.99  0.99  0.99  0.99  
MCH 1.00  0.99  1.00  1.01  0.99  0.99  0.99  0.99  0.98 w 0.98  0.98 tW 1.00  0.98  0.99  0.98 t 0.99  
MCHC 1.00  0.99  0.99  1.00  1.00  0.99  0.99 tw 0.99  0.99 w 0.99  0.99 tw 0.99  0.99  1.00  0.99  1.00  
PLT 0.96  0.94  1.03  0.98  0.95  0.97  1.01  1.08  0.98  0.93 t 1.01  1.10  1.02  0.97  1.03  1.12  
LYMR 0.96  0.98  1.01  0.98  0.98  0.99  1.01  0.99  0.98  1.00  1.01  1.01  1.00  0.98  1.02  1.01  
LYMA 1.03  1.03  1.03  1.21  1.01  1.02  0.94  0.97  0.95  0.96  0.98  1.05  1.10  1.01  1.05  1.10  
diffWBC 
Females 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Lymphocytes -  1.00  -  -  -  1.00  -  -  -  1.00  -  -  -  1.03  -  -  
Neutrophils -  1.01  -  -  -  1.03  -  -  -  1.02  -  -  -  0.97  -  -  
Monocytes -  0.76  -  -  -  0.88  -  -  -  0.94  -  -  -  0.67 dW -  -  
Eosinophils -  0.98  -  -  -  0.85  -  -  -  1.07  -  -  -  0.86  -  -  
ClinChem 
Females 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
ALP 1.03  0.93  0.98  1.03  1.03  0.92  1.02  1.10  1.09  0.94  1.01  1.09  1.03  0.93  0.94  1.05  
ALT 1.01  0.99  0.95  0.96  0.98  1.03  0.99  0.98  0.92  0.88 tw 0.88  1.01  1.09  0.99  0.99  1.02  
AST 1.00  0.96  0.99  0.95  1.08  1.06  1.04  1.08  0.99  0.92 w 0.97  1.06  1.14 dw 1.06  1.05  1.03  
BIL 0.93  1.01  0.92  0.99  1.06  1.03  0.96  1.00  0.96  0.98  0.97  0.95  1.01  1.00  0.95  1.00  
G-TwYST Study A  Main statistical report 
39 
 
ALB 0.99  1.01  1.00  1.00  0.99  1.01  1.01  1.00  1.00  1.02  1.01  0.97  0.98  0.99  1.00  1.01  
TP 0.99  1.00  1.00  1.02  0.99  1.01  1.00  1.03  1.00  1.01  1.00  0.99  0.99  0.99  1.00  1.02  
Glu 0.99  0.96  1.01  1.01  0.95  0.95  0.97  0.93  1.01  0.98  1.04  0.92  0.95  0.98  1.03  0.93  
CHOL 0.97  0.98  0.99  1.04  0.92  0.92  0.95  0.94  0.90 t 0.91  0.92  0.88  0.94  0.94  0.95  1.03  
TAG 0.97  0.99  0.97  1.07  0.90 w 0.92  1.00  0.84  0.87 d 0.91 w 0.99  0.92  0.96  0.97  1.02  0.94  
Crea 1.04  0.99  1.05  1.10  1.02  0.97  1.04  1.15 dT 1.05 tw 1.01  1.06 t 1.11 t 1.03  1.02  1.03  1.14 dTw 
Urea 1.02  1.04  1.08 tW 1.02  1.01  1.02  1.11 Dw 1.09  1.02  1.00  1.10 dTw 1.04  1.06 w 1.03  1.07 tw 1.02  
cHGB 0.96  1.05  0.88  0.91  1.14  1.10  0.98  0.93  0.88 w 1.02  0.96  0.89  1.03  0.97  0.97  0.97  
Ca 1.00  1.00  1.00  1.01  1.01  1.01  1.01  1.01  1.00  1.01  1.01  1.01  1.00  1.00  1.00  1.01  
Cl 1.01  1.01  1.01  0.98 tw 1.01 w 1.01  1.00  0.99  1.01 t 1.01  1.00  0.99  1.01  1.00  1.00  0.99  
K 1.02  1.02  1.01  0.92 t 1.02  1.08 DW 1.01  0.99  1.00  1.03  1.01  1.02  1.03  1.00  1.01  1.00  
Na 1.01  1.00  1.01 t 1.00  1.01 w 1.00  1.01 t 1.00  1.01 tw 1.00  1.00  1.00  1.01 tw 1.00  1.00  1.00  
P 1.06  1.01  1.01  1.00  1.12 tW 1.04  1.08  1.11  0.97  1.00  1.05  1.10  1.07  0.96  0.98  0.97  
Urine 
Females 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
uVol 0.94  0.89  0.90  1.02  1.20  1.17  1.00  1.07  0.89  1.02  1.01  0.92  0.85  0.78  0.93  1.16 w 
uVolW 0.95  0.89  0.95  1.06  1.18  1.15  1.01  1.09  0.87  1.01  1.03  0.95  0.85  0.78 w 0.97  1.15  
uLeu 0.91  1.23  1.04  1.22  1.06  0.95  1.50  0.97  1.06  0.85  0.91  1.30  0.90  1.00  1.12  0.83  
uOsmoll 1.08  1.08  1.04  0.93  0.85  0.84  1.00  0.93  1.21  1.00  0.96  0.99  1.25  1.20  1.07  0.90  
uProtein -  -  -  1.99  -  -  -  1.61  -  -  -  1.61  -  -  -  1.12  
uHemogl -  -  -  0.69  -  -  -  0.96  -  -  -  1.12  -  -  -  0.69  
uKeton 1.02  1.13  1.17  0.76  1.10  1.06  1.15  0.88  1.43 t 0.91  0.84  1.22  1.16  0.91  1.12  0.76  
upH 0.75  0.88  0.89  1.34  1.03  1.16  0.92  1.54 t 0.86  0.95  1.18  1.22  0.98  0.93  0.89  1.18  
Organs 
Females 
NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Kidney -  -  1.07  -  -  -  1.05  -  -  -  1.08 tw -  -  -  1.08 tw -  
Spleen -  -  1.09  -  -  -  0.98  -  -  -  1.04  -  -  -  1.11  -  
Liver -  -  1.02  -  -  -  1.01  -  -  -  1.03  -  -  -  1.03  -  
AdrenGl -  -  1.03  -  -  -  1.01  -  -  -  1.04  -  -  -  1.06  -  
Heart -  -  1.06 w -  -  -  1.08 t -  -  -  1.04  -  -  -  1.07  -  
Uterus -  -  1.05  -  -  -  0.90  -  -  -  1.00  -  -  -  0.99  -  
Ovary -  -  1.11  -  -  -  1.20  -  -  -  1.18  -  -  -  1.23  -  
Brain -  -  1.10 dTW -  -  -  1.08 t -  -  -  1.09 dw -  -  -  1.10 dTW -  
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4.6 Standardised effect sizes 
4.6.1 Method 
EFSA (2011b) defines the standardised effect size (SES) as the effect size measured in SD units, where 
SD is the standard deviation among experimental units. We will assume that in a randomised block 
experiment, like the current G-TwYST study, SD refers to the pooled residual variation. The use of SES 
in EFSA (2011b) was in the context of determination of sample size and power: ‘If experience from 
previous toxicity tests shows an effect size of, say, one SD or less is of little toxicological relevance 
then this can be used to determine sample size in new situations’ (EFSA 2011b). Zeljenková et al 
(2014) followed this example and, without further toxicological motivation, ‘assumed that an SES of 
1.0 SD or less is unlikely to be of toxicological importance’. Consequently, all results of the GRACE 
studies have been reported as confidence intervals on the SES scale (Zeljenková et al, 2014, 2016, 
Schmidt et al 2015, 2017). In this section the same SES graphs are calculated for comparability 
between GRACE and G-TwYST. 
Standardized effect sizes (SES), and their exact 95% confidence intervals, were calculated by means 
of the conf.limits.nct() function in the MBESS R-package, see section 3 in Kelley (2007). Note that, 
since the calculated SES confidence interval is exact, the SES interval does not contain zero if and only 
if the p-value of the corresponding t-test is smaller than 5%. 
4.6.2 Results 
For the results see the companion reports (Goedhart & van der Voet 2018abcd). The number of 
intervals that extend outside the -/+ 1 SD limits equals 106 out of 288 (37%) for the 3-months data, 
102 out of 320 (32%) for the 6-months data, 141 out of 352 (40%) for the 12-months data and 72 out 
of 296 (24%) for the 24-months data. 
4.7 Factorial analysis 
4.7.1 Method 
The purpose of oral toxicity study A in the EU project G-TwYST was to assess the effects of genetically 
modified (GM) maize NK 603, grown both with and without the use of RoundUp, when fed to rats for 
a period of up to two years at incorporation rates of 11% and 33% in the feed. Table 13 lists the 
maize type and incorporation rate of the 5 diets.  
Table 13  Diets used in the 2-year feeding trial study A with GM inclusion rates 11% and 33%. 
Group 
Isogenic maize  
(% of diet) 
NK603 only  
(% of diet) 
NK603 + Roundup 
(% of diet) 
Control 33 0 0 
NK11- 22 11 0 
NK33- 0 33 0 
NK11+ 22 0 11 
NK33+ 0 0 33 
 
The structure of diets is a 2 by 2 factorial design for the GM feeding groups with factors GM inclusion 
rate (IR, 11% or 33%) and use of Roundup (RU, -  or +), with an added control for the non-GM control 
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group. This structure allows a more sensitive analysis, integrating over the five dose group, according 
to the model: 
𝑦𝑦0𝑊𝑊 = 𝜇𝜇 + 𝛿𝛿𝑊𝑊 + 𝜖𝜖𝑖𝑖𝑖𝑖𝑊𝑊   for data in the Control (non-GM) group (i = 0) 
𝑦𝑦𝑖𝑖𝑖𝑖𝑊𝑊 = 𝜇𝜇 + 𝐺𝐺𝐺𝐺 + 𝐼𝐼𝑅𝑅𝑖𝑖 + 𝑅𝑅𝑈𝑈𝑖𝑖 + 𝑊𝑊𝑖𝑖𝑡𝑡𝑖𝑖𝑖𝑖 + 𝛿𝛿𝑊𝑊 + 𝜖𝜖𝑖𝑖𝑖𝑖𝑊𝑊 for data in GM groups, 𝑊𝑊 = 1,2; 𝑗𝑗 = 1,2. 
In this model the stochastic terms are 𝛿𝛿𝑊𝑊  for block effects and 𝜖𝜖𝑖𝑖𝑖𝑖𝑊𝑊 for residual effects. The fixed term 
𝐺𝐺𝐺𝐺 models the difference between the four GM groups (averaged) and the control. This term can 
only be interpreted if the other three fixed terms can be assumed to be zero. The main effect 𝐼𝐼𝑅𝑅2 −
𝐼𝐼𝑅𝑅1 models the difference between the groups with inclusion rates 33% and 11%, and similarly, the 
main effect 𝑅𝑅𝑈𝑈2 − 𝑅𝑅𝑈𝑈1 models the difference between the groups with and without Roundup. These 
main effects are only useful when there is no interaction, modelled by 𝑊𝑊𝑖𝑖𝑡𝑡𝑖𝑖𝑖𝑖, between GM inclusion 
rate and Roundup. 
4.7.2 Results 
This section summarises the main findings reported in the companion reports (Goedhart & van der 
Voet 2018abcd). Estimated ratios of factorial effects are shown in Table 15 and Table 16, for male 
and female rats, respectively. The frequencies of the significant results among all 1192 tests are 
shown in Table 14. RoundUp effects at 3 and 12 months, as well as interactions at 6 and 12 months 
were seen in more than 5% of tests. 
 
Table 14 Absolute and relative frequencies of significant results (P<0.05) in testing factorial 
effects. Males and females combined. Frequencies significantly higher (P<0.05) than the 
nominal test level of 5% by an exact binomial test are shown with a red background. 
  3 months 6 months 12 months 24 months all 
GM vs. non-GM 3/72 (4%) 1/80 (1%) 8/88 (9%) 1/74 (1%) 13/314 (4%) 
GM incl. rate 7/67 (10%) 2/70 (3%) 6/77 (8%) 3/68 (4%) 18/282 (6%) 
RoundUp 8/67 (11%) 3/70 (4%) 11/77 (14%) 0/68 (0%) 22/282 (8%) 
interaction 5/72 (5%) 10/80 (12%) 11/88 (12%) 6/74 (8%) 32/314 (10%) 
all 23/278 (8%) 16/300 (5%) 36/330 (11%) 10/284 (4%) 85/1192 (7%) 
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Table 15 Estimated ratios of factorial effects for male rats. Only ratios for significant effects (P<0.05) are shown with a red background. Cells containing 
‘x’ refer to non-significant effects, while cells containing ‘-‘ indicate no data or no analysis. 
Males 
Weights 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Weight x x x x x x x x x x x x x x x 1 / 0.99 / 0.96 / 1.04 
growthRate x x x x x x 1.10 x x x 1.08 x 1 / 1.01 / 1.01 / 1.01 x x x 
FeedMean x x x x x x 1.03 x x 1.02 1.03 x 1 / 0.98 / 0.99 / 1.02 x x x 
Males 
Haematology 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
WBC x x x x x x 1.12 x x x x x x 1 / 1.24 / 1.20 / 1.10 x x 
RBC x x x x x x x x x x x x x x x x 
HGB x x x x x x x x x x x x x x x x 
HCT x x x x x x x x x x x x x x x x 
MCV x x x x x x x x x x x x x x x x 
MCH x x x x x x x x x x x x x x x x 
MCHC x x x x x x x x 0.99 x x x x x x x 
PLT x x x x x x 1.07 x x x x x x x x x 
LYMR x x x x x x x x x x x x x x x x 
LYMA x x x x x x x x x x x x x 1 / 1.24 / 1.23 / 1.14 1 / 1.20 / 1.08 / 1.07 x 
Males 
diffWBC 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Lymphocytes - x - - - x - - - x - - - x - - 
Neutrophils - x - - - x - - - x - - - x - - 
Monocytes - 0.82 - - - x - - - x - - - x - - 
Eosinophils - x - - - x - - - x - - - x - - 
Males 
ClinChem 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
ALP x x x x x x x 0.83 x x x x x x x x 
ALT x x x x x x x x x x x x x x x x 
AST x x x x x x x x x x x x x x x x 
BIL x x x x x x x x x x x x x x x x 
ALB x x x x x x x x x x x x x x x 1 / 1.06 / 1.05 / 1.01 
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TP x x x x x x x x x x x x x x x x 
Glu x x x x x x x x 1.06 1.05 x x x x x x 
CHOL x x x x x x x x x x x x x x x x 
TAG x x x x x x x x x x x x x x x x 
Crea x x x x x x x x x x x x x x x x 
Urea x x x x x x x x x x x x x x x x 
cHGB x x x x x x x x x x x x x x x x 
Ca x x x x x x x x x x x x x x x 1 / 0.98 / 0.98 / 1.00 
Cl x x 0.99 x x x x x x x x x x x x x 
K x x x x x x x x x x x x x x x x 
Na x x x x 1 x x x x x x x x x x x 
P x x x x x x x x x x x x x x 1 / 1.08 / 1.02 / 1.01 1 / 0.85 / 0.92 / 0.99 
Males 
Urine 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
uVol x x x x x x x x x x x x x 1 / 0.75 / 0.85 / 0.97 1 / 0.83 / 0.85 / 0.96 x 
uVolW x x x x x x x x x x x x x 1 / 0.75 / 0.85 / 0.95 1 / 0.83 / 0.83 / 0.93 x 
uLeu x x x x 1.35 x x 1.30 x x x x x x x x 
uOsmoll x x x x x x x x x x x x x 1 / 1.32 / 1.19 / 1.05 1 / 1.17 / 1.13 / 1.07 x 
uProtein - - - x - - - x - - - x - - - x 
uHemogl - - - x - - - x - - - x - - - x 
uKeton x x x x x x 1.49 x x x 0.70 x x x x x 
upH x x x x x x x x x x x x x x 1 / 1.20 / 1.26 / 0.98 x 
Males 
Organs 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Kidney - - x - - - x - - - x - - - x - 
Spleen - - x - - - x - - - x - - - x - 
Liver - - x - - - x - - - x - - - x - 
AdrenGl - - x - - - x - - - 0.92 - - - x - 
Heart - - x - - - x - - - 0.95 - - - x - 
Testis - - x - - - x - - - x - - - x - 
Epididymis - - x - - - x - - - x - - - 1 / 0.92 / 0.85 / 0.92 - 
Brain - - x - - - x - - - 0.95 - - - x - 
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Table 16 Estimated ratios of factorial effects for female rats. Only ratios for significant effects (P<0.05) are shown with a red background. Cells 
containing ‘x’ refer to non-significant effects, while cells containing ‘-‘ indicate no data or no analysis. 
Females 
Weights 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Weight x x x x x x x x x x x x x x x x 
growthRate x x x x x x x x x x x x x x x x 
FeedMean 1.02 x x x x x 1.03 x x x x x 1 / 0.98 / 0.98 / 1.01 x x x 
Females 
Haematology 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
WBC x x x x x x x x x x x x x x 1 / 0.88 / 0.91 / 0.99 x 
RBC x x x x x x x x x x 1.02 x x x x x 
HGB x x x x x x x x x x x x x x x x 
HCT x x x x x x x x x x x x x x x x 
MCV x x x x x x x 0.98 x x 0.99 x x x x x 
MCH x x x x x x x x 0.99 x 0.99 x x x x x 
MCHC x x 0.99 x x x x x 0.99 x x x x x x x 
PLT x x x x x x x x 1.04 x x x x x x x 
LYMR x x x x x x x x x x x x x x x x 
LYMA x x x x x x x x x x x x x x 1 / 0.88 / 0.91 / 0.99 x 
Females 
diffWBC 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Lymphocytes - x - - - x - - - x - - - x - - 
Neutrophils - x - - - x - - - x - - - x - - 
Monocytes - x - - - x - - - x - - - 1 / 1.16 / 1.22 / 0.88 - - 
Eosinophils - x - - - x - - - x - - - x - - 
Females 
ClinChem 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
ALP x x x x x x x x x x x x x x x x 
ALT x x x x x 1.08 x x x 0.93 x x 1 / 0.96 / 0.91 / 1.08 x x x 
AST x x x x 1.12 1.13 x x x x x x x x x x 
BIL x x x x 1.09 x x x x x x x x x x x 
ALB x x x x x x x x x x x x x x x x 
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TP x x x x x x x x x x x x x x x x 
Glu x x x x x x x x x x 1.05 x x x x x 
CHOL x x x x x x x x x x x x x x x x 
TAG x x x x x x x x x x x x 1 / 0.93 / 0.89 / 0.99 x x x 
Crea x x 1.04 1.12 x x x x x x x x x x x x 
Urea x x 1.09 x x x x x x x x x x x x x 
cHGB x x x x 1.19 x x x x x x x x x x x 
Ca x x x x x x x x x x x x x x x x 
Cl 1.01 x x x x x x x x x x x x x x x 
K x x x x x x x x x x x x x 1 / 1.06 / 1.02 / 0.99 x 1 / 1.08 / 1.12 / 1.09 
Na 1.01 x 1.01 x x x x x x x x x x x x x 
P x x x x 1.08 x x x x x x x x x 1 / 1.03 / 1.32 / 0.99 1 / 1.11 / 1.10 / 0.97 
Females 
Urine 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
uVol x x x x x x x x 0.82 x x x x 1 / 1.32 / 1.15 / 0.88 x x 
uVolW x x x x x x x x 0.81 x x x x 1 / 1.30 / 1.14 / 0.88 x x 
uLeu x x x x x x x x x x x x x x x x 
uOsmoll x x x x x x x x 1.29 x x x x 1 / 0.78 / 0.93 / 1.11 x x 
uProtein - - - x - - - x - - - x - - - x 
uHemogl - - - x - - - x - - - x - - - x 
uKeton x x x x x x x x x x 0.84 x x x x x 
upH x x x x 1.24 x x x x x x x x x 1 / 1.03 / 1.32 / 0.99 x 
Females 
Organs 
GM vs. non GM 33% vs. 11% RU+ vs. RU- Interaction  (NK11- / NK33- / NK11+ / NK33+) 
3 6 12 24 3 6 12 24 3 6 12 24 3 6 12 24 
Kidney - - 1.07 - - - x - - - x - - - x - 
Spleen - - x - - - x - - - x - - - x - 
Liver - - x - - - x - - - x - - - x - 
AdrenGl - - x - - - x - - - x - - - x - 
Heart - - 1.06 - - - x - - - x - - - x - 
Uterus - - x - - - x - - - x - - - x - 
Ovary - - x - - - x - - - x - - - x - 
Brain - - 1.09 - - - x - - - x - - - x - 
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4.8 Correlation analysis 
4.8.1 Method 
For single variables the difference between a GM feed group and the control group is quantified by 
the ratio of the responses. These can then be compared to given limits (as in Figure 13 - Figure 16) or 
to limits calculated from historical data (as in Figure 9 - Figure 12). 
For a toxicological interpretation it may be helpful to see results for variables that simultaneously 
relate to the same pathological endpoint. Bivariate plots were prepared showing the patterns for 
each pair for three variables related to liver disorder (relative liver weight, ALP, CHOL) and three 
variables related to kidney disorder (relative kidney weight, Urea, Crea). The ten points in each graph 
are based on the cage means in the ten blocks of the study. This analysis was only performed for the 
12 months data, which was the only time point where organ weights have been measured. 
For comparison, the proposed target effect sizes of Hong et al (2017) are included in the plots as 
horizontal and vertical lines (together with lines at ratio 1 for reference). It can be noted that similar 
plots could have been made using the equivalence limit scaled differences (ELSDs) as presented in 
Figure 9 - Figure 12. 
4.8.2 Results 
This section summarises the main findings reported in the companion report (Goedhart & van der 
Voet 2018c). 
The correlation plots for three liver-related and three kidney-related variables in males and females 
are shown in Figure 18 - Figure 21. For males there were significant positive correlations between 
Urea and Crea for all comparisons (Figure 19), without accompanying correlations with the relative 
Kidney weights. Further significant (positive) correlations were found between ALP and CHOL in 
males, and between Kidney and Urea in females. Simultaneous exceedance of the threshold for two 
variables was only observed for Kidney and Urea for a single cage in females; the accompanying Crea 
value was close to the threshold for this cage. 
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Figure 18 Pairwise results for variables with set target effect sizes related to liver damage in Males 
after 12 months. In each row there are four graphs corresponding to the four GM feed 
groups. Points represent the ratio of the cage mean for the GM group vs. the cage mean 
for the control feed in ten blocks. Horizontal and vertical lines represent a ratio of 1 and 
the target effect sizes from Hong et al. (2017). 
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Figure 19 Pairwise results for variables with set target effect sizes related to kidney damage in 
Males after 12 months. In each row there are four graphs corresponding to the four GM 
feed groups. Points represent the ratio of the cage mean for the GM group vs. the cage 
mean for the control feed in ten blocks. Horizontal and vertical lines represent a ratio of 
1 and the target effect sizes from Hong et al. (2017). 
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Figure 20 Pairwise results for variables with set target effect sizes related to liver damage in 
Females after 12 months. In each row there are four graphs corresponding to the four 
GM feed groups. Points represent the ratio of the cage mean for the GM group vs. the 
cage mean for the control feed in ten blocks. Horizontal and vertical lines represent a 
ratio of 1 and the target effect sizes from Hong et al. (2017). 
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Figure 21 Pairwise results for variables with set target effect sizes related to kidney damage in 
Females after 12 months. In each row there are four graphs corresponding to the four 
GM feed groups. Points represent the ratio of the cage mean for the GM group vs. the 
cage mean for the control feed in ten blocks. Horizontal and vertical lines represent a 
ratio of 1 and the target effect sizes from Hong et al. (2017). 
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5 Summary and discussion 
In this report the data from G-TwYST study A have been analysed following eight approaches. For 
comparisons between a GM feeding group and the control feed for a single variable, these 
approaches were two forms of analysing survival/mortality (4.1, 4.2), two forms of equivalence 
analysis (4.3 4.4), the traditional approach focusing on significant differences (4.5), and the 
standardised effect size (SES) approach (4.6). In addition, a factorial analysis (4.7, also 4.1, 4.2) and a 
correlation analysis (4.8) allowed some limited forms of integration over dose groups or variables, 
respectively. 
Survival analysis (4.1) showed few differences between the five feeding groups. The mortality rate at 
24 months (4.2) was increased for male animals in the NK33+ group relative to the Control group. In 
a factorial analysis, there was an indication that RoundUp could have increased the hazard and the 
mortality rate at 24 months for the males. It should be noted that 3 significant results (with P-values 
0.03, 0.03 and 0.04, respectively) found in 48 comparisons amount to 6%, which is close to the 
nominal level of the tests (5%). 
Among the two forms of equivalence analysis, the approach with given external equivalence limits 
(4.4) is the simpler one. It could be preferred if toxicologists were able to set external equivalence 
limits for all relevant variables based on their expert knowledge. In the current report it was applied 
to nine variables, for which Hong et al (2017) recently proposed targeted effect sizes. Obviously, the 
uncertainty in setting these targeted effect sizes is not accounted for in the equivalence analysis 
using these fixed limits. 
However, external equivalence limits are often not available, and toxicologists notice many 
uncertainties about the impact of toxicological effects. Moreover, they find it often difficult to come 
to a conclusion on such equivalence limits. For such cases, the equivalence analysis which bases 
equivalence on normal variation in historical non-GM data (4.1) may be an attractive alternative. This 
approach assumes that test facilities perform whole-food studies with rodents on a routine basis, 
such that variations between non-GM foods and between experimental units which are seen in 
historical studies have a relevance for the current study. In the current report, the approach could be 
applied to 27 variables measured at 3 months and 30 variables measured at 6 months. These 
variables were also observed in five preceding studies at 3 months  in the same test facility in the 
GRACE project. Van der Voet et al (2017) discuss this new method which was developed in the G-
TwYST project.  In the results from study A it appeared that the residual variance within the feeding 
groups was generally increasing after 6 months. For this reason the equivalence testing method 
against historical data could not be applied with success for the data obtained at 12 months and 24 
months. 
For the data at 3 months and 6 months, and using the approach based on the historical GRACE data 
given tentative settings for regulatory parameters, equivalence was established in 99.8% of cases 
(411/412) as long as the residual variance in the current study was not larger than 150% of the 
residual variance in the historical studies. The regulatory parameters are the testing level (set at 5%) 
for all approaches, and two parameters for the new G-TwYST equivalence approach: the desired 
power (set at 95%) and the minimum sample size per group (set equal to the sample sizes in the 
current study, i.e. 35 for the weight variables and 20 for haematology, differential white blood cell 
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counts and clinical biochemistry). Note that test results could be different if these parameters were 
chosen differently.  
For the 44 cases where the variance in the current study was more than 150% of that in the historical 
study, the conclusion must be that these  discrepancies must be solved first before this approach to 
equivalence testing would be feasible. Either, the precision was insufficient in the current study or 
the precision was under-estimated in the historical study, and better reference data should be 
gathered. This is obviously true at 12 and 24 months, for which currently no historical reference data 
from the same test facility were available. If on the other hand it would be thought that the lower 
precision in the current study has to be accepted, then the study should be repeated with higher 
numbers of experimental units. 
Using the alternative equivalence testing method using fixed target effect sizes, equivalence was 
established in 94% of cases (211/224), with the large residual variation in body weight, WBC and 
LYMA at 24 months being responsible for the negative results. 
In all cases where equivalence was not established by means of the statistical test and the variance 
ratio was below 1.5, the median estimate was still in the equivalence region. Therefore, in the 
terminology of EFSA (2011a), these cases are still classified as ‘equivalence more likely than lack of 
equivalence’.  
As noted by EFSA (2011b), separate analysis of many endpoints, most of which are not expected to 
differ between treatment groups, results in a large number of statistical tests. This will lead to the 
issue of multiple testing (multiplicity). As long as the variance in the current study was not larger than 
150% of the variance in the historical studies, there was only one non-significant equivalence test 
and therefore the rate of non-equivalence was lower than the nominal level of the tests (which was 
set at 5%). In this report, we have not tried to adapt equivalence tests for multiplicity. However, it 
should be pointed out that a recently proposed approach to adjusting for multiplicity based on the 
False Discovery Rate (FDR) is not appropriate. Hong et al (2017) used adjusted p values using the FDR 
method for multiplicity adjustment. This means that effectively most p values are much larger 
(indicating less significant differences) than in a standard unadjusted analysis. This may explain why 
they report that ‘no treatment-related differences were observed’, although there were some 150 
continuous endpoints in total. This complete absence of statistically significant differences is very 
much at odds with what is commonly found (e.g. in the GRACE, G-TwYST, and GMO90+ studies). 
Indeed, the absence of significant differences in Hong et al (2017) could be a direct consequence of 
using the FDR adjustment. It is doubtful whether the use of the FDR-correction makes sense in food 
safety testing (EFSA 2010, van der Voet 2018). It controls false discoveries, and is therefore 
connected to difference testing, where false positives are considered as error of the first kind. i.e. 
one wants to have a small probability of erroneously reporting a difference. In the context of 
equivalence testing the statistical hypotheses are reversed, and false negatives are the error of the 
first kind, i.e. one wants to have a small probability of erroneously reporting equivalence. 
Consequently, the FDR concept is addressing the wrong type of error. 
Classical analysis following OECD guidance is only focusing on finding differences, not equivalences. 
Only for the data at 12 months the rate of significant results was higher than the nominal  5% 
significance level, i.e. 11% when the t-test was applied. The scheme advocated by OECD contains 
several adaptations. First, a multiplicity correction by using Dunnett’s test rather than the straight-
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forward t-test is proposed for the fact that four groups are compared at the same time to the control 
group. Thus, applying Dunnett’s test the number of significant cases at the 5% significance level was 
reduced to 3% of all comparisons for 12 months data, i.e. similar to the nominal error level). 
However, a multiplicity correction may be wrong for the same reason why the FDR method was 
wrong: if we are primarily interested in safety and equivalence, then the roles of the statistical 
hypotheses are reversed, and corrections as used in Dunnett’s test address the wrong type of error. 
In this work confidence intervals were also expressed and plotted as Standardised Effect Size (SES), 
see EFSA (2011b), in order to allow a comparison with SES results for the preceding GRACE project 
(Schmidt and Schmidtke 2014, Schmidt et al 2015ab, 2016, 2017, Zeljenková et al 2014, 2016). SES, 
also known as Cohen’s 𝑑𝑑, is often used in meta-analyses to show the results of different variables in 
the same plot. Reporting and graphically displaying effect sizes was described in Schmidt et al (2016) 
as a way ‘to avoid the yes/no decision trap of statistical tests and to illustrate the size of effects in the 
context of biological relevance’. However, in the absence of clear limit values for biological relevance, 
these authors had to build on the arbitrary EFSA example, where effects of ±1 SD were assumed to 
be unlikely to be of toxicological importance. Schmidt et al (2016) already concluded that the pooled 
standard deviation SD of individual measurements ‘is a priori not expected to be directly related to 
biological relevance’, and Schmidt et al (2017) warned that ‘it should therefore be kept in mind that 
future decisions on relevant equivalence limits may influence the equivalence results’. The results of 
the current G-TwYST study, where 97% of all intervals extended outside the ±1 SD limits, confirms 
the pattern observed in GRACE. Whereas, displaying the confidence intervals indeed gives a richer 
view on the results than just reporting yes/no decisions, the scale of the SES plots does not seem the 
best choice for equivalence assessments. As Hong et al (2017) remark, the value of SES to support 
data interpretation is limited. Alternatively scaled effect sizes, such as those presented in section 4.3 
can be preferred, because the scaling factor (the equivalence limit) is based on data analysis of in this 
case historical data, rather than being an arbitrary value. It can be noted, however, that this 
approach was not available for the GRACE project, because of lack of historical data in the same test 
facility. 
Factorial analyses for single variables allowed to consider effects pooled over more than two groups, 
thus providing more powerful tests for main effects in the absence of interaction. However, this 
approach was in the current work restricted to the testing of differences. In principle, it could be 
further developed for the equivalence tests. 
Most statistical analyses in this report have considered variables one by one, collecting the results 
only in a joint table or plot for ease of interpretation. However, toxicologists often stress that effects 
should be judged together. Wherever a prior hypothesis exists that links multiple variables, these 
may sometimes be translated in a function of those variables. For example, there is a biological 
connection between the pancreas and the regulation of glucose, which leads to a prior expectation 
of a negative correlation between pancreas weight and serum glucose. It may then be sensible to 
perform difference and equivalence testing for an additional variable such as the ratio or log-ratio of 
these variables. Such ratios have not been defined in the current study. 
Another tool to study variables together is pairwise plotting of results per experimental unit. In 
section 4.8 this was done for three variables related to liver damage and three variables related to 
kidney damage. The rationale was that correlations between variables would show up in these plots, 
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but this was hardly observed in these cases. To assist in the interpretation, the effects were plotted 
together with proposed target effect sizes. Most effects were below these limits also at the cage 
level (as was already observed for the means in section 4.4). We may conclude that correlations 
between these variables related to the same organ are nevertheless not prominent as long as the 
effects are within the targeted range. Of course, correlations could be (and are expected to be) more 
evident for effect sizes that would exceed the limits by large amounts. 
A more detailed approach to testing than reported here would also be possible based on a more 
detailed consultation with toxicologists. For example, nephrotoxic effects can lead to decreased or 
increased kidney weights. However, in both of these cases, the toxicologists would expect to see 
increased urea (Urea) and/or creatinine (Crea) levels. In addition, there might be a decreased level of 
glucose in the urine (Glu) or an increased level of amino acids, but these effects are less predictable. 
Increases in Urea or Crea may indicate nephrotoxic effects that are not yet discernible as deviating 
kidney weights. It is concluded that increased Urea and/or Crea levels are the primary indicators of 
kidney damage, and only increased levels represent a toxicological concern. Considering observed 
normal ranges, an increase by 50% in at least one of the two key variables could be seen as 
potentially concerning, and provide a level to be used as equivalence limit. Specific hypotheses to be 
tested for the differences Δ (on the log scale) between the treatment groups (GM vs. comparator) 
would then be as follows. 
Difference tests:  
 𝑃𝑃0:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈) = 0 vs. 𝑃𝑃1:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈) > 0 
 𝑃𝑃0:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈) = 0 vs. 𝑃𝑃1:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈) > 0 
Equivalence tests:  
 𝑃𝑃0:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈) = 𝐸𝐸𝐿𝐿𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈 vs 𝑃𝑃1:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈) < 𝐸𝐸𝐿𝐿𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈 
 𝑃𝑃0:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈) = 𝐸𝐸𝐿𝐿𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈 vs. 𝑃𝑃1:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈) < 𝐸𝐸𝐿𝐿𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈 
where 𝐸𝐸𝐿𝐿𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈 =  𝐸𝐸𝐿𝐿𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈 = log (1.5). 
In cases when a difference is found or an equivalence cannot be shown, the other variables (kidney 
weight, Glu, amino acids) may provide further interpretation to the toxicologist. These variables are 
therefore considered as secondary: the results can be summarised in terms of absolute values and 
confidence intervals for Δ (also shown graphically), but they would not be part of the testing 
framework based on primary variables. However, fine-tuning of statistical analyses as suggested here 
demands a large investment of time from both toxicologists and statisticians, and it will be very 
difficult to perform such exercises across the whole spectrum of endpoints. 
  
G-TwYST Study A  Main statistical report 
55 
 
References 
 
EFSA (2010). Statistical considerations for the safety evaluation of GMOs. EFSA Journal 2010, 8, 1250. 
http://dx.doi.org/10.2903/j.efsa.2010.1250. 
EFSA (2011a). Scientific Opinion on Guidance for risk assessment of food and feed from genetically 
modified plants. EFSA Journal 2011;9(5): 2150. [37 pp.]  
http://dx.doi.org/10.2903/j.efsa.2011.2150. 
EFSA (2011b). EFSA guidance on conducting repeated-dose 90-day oral toxicity study in rodents on 
whole food/feed. EFSA Journal 2011;9(12):2438 [21 pp.] doi:10.2903/j.efsa.2011.2438. 
EFSA (2013). Considerations on the applicability of OECD TG 453 to whole food/feed testing. EFSA 
Journal 2013;11(7):3347, 18 pp. doi:10.2903/j.efsa.2013.3347 
EFSA (2014). Explanatory statement for the applicability of the Guidance of the EFSA Scientific 
Committee on conducting repeated-dose 90-day oral toxicity study in rodents on whole 
food/feed for GMO risk assessment. EFSA Journal 2014;12(10):3871, 25 pp., 
doi:10.2903/j.efsa.2014.3871  
Goedhart, P.W. & van der Voet, H. (2017). G TwYST Study B. a 90-day toxicity study in rats fed GM 
maize NK603. Statistical report. Report 31.10.17, Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study A. Combined chronic toxicity and 
carcinogenicity study in rats fed GM maize NK603. Statistical report, 3 months. Report 
33.02.18, Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study A. Combined chronic toxicity and 
carcinogenicity study in rats fed GM maize NK603. Statistical report, 6 months. Report 
34.02.18, Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study A. Combined chronic toxicity and 
carcinogenicity study in rats fed GM maize NK603. Statistical report, 12 months. Report 
35.02.18, Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study A. Combined chronic toxicity and 
carcinogenicity study in rats fed GM maize NK603. Statistical report, 24 months. Report 
36.02.18, Biometris, Wageningen, The Netherlands.  
Hong B, Du Y, Mukerji P, Roper JM, Appenzeller LM (2017). Safety assessment of food and feed from 
GM crops in Europe: Evaluating EFSA’s alternative framework for the rat 90-day feeding study. 
Journal of Agricultural and Food Chemistry, 65(27): 5545-5560. 
http://dx.doi.org/10.1021/acs.jafc.7b01492   
Kelly K (2007). Confidence intervals for Standardized Effect Sizes: Theory, Application and 
Implementation. Journal of Statistical Software, 20(8). 
McCullagh, P. & Nelder, J.A. (1989). Generalized linear models. Chapman and Hall. London. 
OECD (1998). Test Guideline 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents, OECD 
Publishing, Paris. http://dx.doi.org/10.1787/9789264070707-en 
G-TwYST Study A  Main statistical report 
56 
 
OECD (2014). Guidance Document 116 on the Conduct and Design of Chronic Toxicity and 
Carcinogenicity Studies, Supporting Test Guidelines 451, 452 and 453: Second edition, OECD 
Publishing, Paris. http://dx.doi.org/10.1787/9789264221475-en 
Schmidt K, Schmidtke J (2014). Statistical analysis report project GRACE, Statistical Analysis of A) 90-
day feeding study in rats with Monsanto MON810 maize B) 90-day feeding study in rats with 
Pioneer MON810 maize. Version 2.01. https://www.cadima.info/index.php/area/selectStudy/3  
Schmidt K, Schmidtke J, Schmidt P (2015a) Statistical analysis report project GRACE, Statistical 
analysis of chronic toxicity (1-year) study of rats with MON810 maize. Version 2.02. 
https://www.cadima.info/index.php/area/selectStudy/4  
Schmidt K, Schmidtke J, Schmidt P (2015b) Statistical analysis report project GRACE, Statistical 
analysis of repeated dose 90-day oral toxicity/longitudinal study in rodents with MON810 
maize. Version 2.00. https://www.cadima.info/index.php/area/selectStudy/5 
Schmidt K, Schmidtke J, Kohl C, Wilhelm R, Schiemann J, van der Voet H, Steinberg P (2016). 
Enhancing the interpretation of statistical P values in toxicology studies – implementation of 
linear mixed models (LMMs) and standardized effect sizes (SESs). Archives of Toxicology, 90: 
731–751. http://dx.doi.org/10.1007/s00204-015-1487-8  
Schmidt K, Schmidtke J, Schmidt P, Kohl C, Wilhelm R, Schiemann J, van der Voet H, Steinberg P 
(2017). Variability of control data and relevance of observed group differences in five oral 
toxicity studies with genetically modified maize MON810 in rats. Archives of Toxicology, 91(4): 
1977-2006. https://dx.doi.org/10.1007/s00204-016-1857-x  
van der Voet H (2018). Safety assessments and multiplicity adjustment: comments on a recent paper. 
J. Agric. Food Chem.  http://dx.doi.org/10.1021/acs.jafc.7b03686 
van der Voet H, Goedhart PW, Schmidt K (2017). Equivalence testing using existing reference data: an 
example with genetically modified and conventional crops in animal feeding studies. Food and 
Chemical Toxicology, 109, 472-485. https://doi.org/10.1016/j.fct.2017.09.044 
VSN International (2015). Genstat for Windows 18th Edition. VSN International, Hemel Hempstead, 
UK. www.Genstat.co.uk  
Williams, D.A. (1982). Extra-binomial variation in logistic linear model. Applied Statistics, 31, 144-148. 
Zeljenková D, Ambrušová K, Bartušová M, Kebis A, Kovrižnych J, Krivošíková Z, Kuricová M, Líšková A, 
Rollerová E, Spustová V, Szabová E, Tulinská J, Wimmerová S, Levkut M, Révajová V, Ševčíková 
Z, Schmidt K, Schmidtke J, La Paz JL, Corujo M, Pla M, Kleter GA, Kok EJ, Sharbati J, Hanisch C, 
Einspanier R, Adel-Patient K, Wal J-M, Spök A, Pöting A, Kohl C, Wilhelm R, Schiemann J, 
Steinberg P (2014). 90-day oral toxicity studies on two genetically modified maize MON810 
varieties in Wistar Han RCC rats (EU 7th Framework Programme project GRACE). Archives of 
Toxicology, 88: 2289-2314 https://dx.doi.org/10.1007/s00204-016-1798-4  
G-TwYST Study A  Main statistical report 
57 
 
Zeljenková D, Aláčová R, Ondrejková J, Ambrušová K, Bartušová M, Kebis A, Kovrižnych J, Rollerová E, 
Szabová E, Wimmerová S, Černák M, Krivošíková Z, Kuricová M, Líšková A, Spustová V, Tulinská 
J, Levkut M, Révajová V, Ševčíková Z, Schmidt K, Schmidtke J, Schmidt P, La Paz JL, Corujo M, 
Pla M, Kleter GA, Kok EJ, Sharbati J, Bohmer M, Bohmer N, Einspanier R, Adel-Patient K, Spök 
A, Pöting A, Kohl C, Wilhelm R, Schiemann J, Steinberg P (2016). One-year oral toxicity study on 
a genetically modified maize MON810 variety in Wistar Han RCC rats (EU 7th Framework 
Programme project GRACE). Archives of Toxicology, 90: 2531-2562. 
https://dx.doi.org/10.1007/s00204-016-1798-4 
Zeljenková D, Steinberg P (2015). Final study plan combined chronic toxicity and carcinogenicity 
study in rats fed GM maize NK603. G-TwYST GMP Two Year Safety Testing, Study 632165 
B/2016/GLP. 
https://www.g-twyst.eu/files/Final%20study%20plans/Combined_chronic_toxicity-
carcinogenicity_%20feeding_trial_study_plan_25.05.2015_final.pdf. 
 
  
G-TwYST Study A  Main statistical report 
58 
 
List of Tables 
 
Table 1 Number of planned observations per endpoint category per feeding group and sex at 3, 6, 
12 and 24 months in study A. The number of observations at 24 months is subdivided in a 
group for animals that died prematurely and animals that survived for 24 months. 
Table 2 Feeding groups and coding of feeds in study A. 
Table 3 Skeleton analysis of variance with degrees of freedom for cage means for a single sex. 
Table 4 List of grouped variables with abbreviated names, descriptions and measurement units. 
Grouping is indicated by the headers in the first column. The Grace column indicates 
whether the same variable was measured in the GRACE project which consisted of 3 
months studies. Variables given in red are not statistically analysed (see companion 
reports for details). The months 24p for Organ weights denote the animals that died 
prematurely, i.e. before the end of the trial. 
Table 5 Feeds which were used in the five GRACE studies with reference feeds in bold. 
Table 6 Mortality of males and females after 3, 6, 12 and 24 months. Mortality of a cage is defined 
as mortality of the fist animal in the cage. 
Table 7 Summary of equivalence tests employing historical data. 
Table 8 Targeted effect sizes from Table 1 in Hong et al (2017) along with their implied lower and 
upper limits on the ratio scale and on the log-ratio scale. 
Table 9 Summary of equivalence tests with fixed target effect sizes. 
Table 10 Absolute numbers and relative frequencies of significant results (P<0.05) in classical tests 
comparing GM groups to the non-GM group, combined for males and females. For the 
three individual tests, frequencies significantly higher (P<0.05) than the nominal test level 
of 5% by an exact binomial test are shown with a red background. 
Table 11 Estimated ratios of GM groups versus the non-GM control group for male rats for months 
3, 6, 12 and 24. Significant ratios are marked, with red background colouring, as follows: 
D: P<0.01 by Dunnett-test, d: P<0.05 by Dunnett-test, T: P<0.01 by t-test but not by 
Dunnett-test, t: P<0.05 by t-test but not by Dunnett-test, W: P<0.01 by Wilcoxon signed 
rank test, w: P<0.05 by Wilcoxon signed rank test. 
Table 12 Estimated ratios of GM groups versus the non-GM control group for female rats for 
months 3, 6, 12 and 24. Significant ratios are marked, with red background colouring, as 
follows: D: P<0.01 by Dunnett-test, d: P<0.05 by Dunnett-test, T: P<0.01 by t-test but not 
by Dunnett-test, t: P<0.05 by t-test but not by Dunnett-test, W: P<0.01 by Wilcoxon 
signed rank test, w: P<0.05 by Wilcoxon signed rank test. 
Table 13  Diets used in the 2-year feeding trial study A with GM inclusion rates 11% and 33%. 
Table 14 Absolute and relative frequencies of significant results (P<0.05) in testing factorial effects. 
Males and females combined. Frequencies significantly higher (P<0.05) than the nominal 
test level of 5% by an exact binomial test are shown with a red background. 
G-TwYST Study A  Main statistical report 
59 
 
Table 15 Estimated ratios of factorial effects for male rats. Only ratios for significant effects 
(P<0.05) are shown with a red background. Cells containing ‘x’ refer to non-significant 
effects, while cells containing ‘-‘ indicate no data or no analysis. 
Table 16 Estimated ratios of factorial effects for female rats. Only ratios for significant effects 
(P<0.05) are shown with a red background. Cells containing ‘x’ refer to non-significant 
effects, while cells containing ‘-‘ indicate no data or no analysis. 
  
G-TwYST Study A  Main statistical report 
60 
 
List of Figures 
 
Figure 1 Mean body weights (g) versus week for each feeding group for male rats (top) and for 
female rats (bottom). 
Figure 2 Mean body weights gain (g/day/animal) versus week for each feeding group for male rats 
(top) and for female rats (bottom). 
Figure 3 Mean feed consumption (g/day/animal) versus week for each feeding group for male rats 
(top) and for female rats (bottom). 
Figure 4 Kaplan-Meier estimates of the survival curves for all 350 rats per sex (left figures), and for 
cages (right figures) where the event per cage is the day of death of the first animal. 
Figure 5 Hazard ratios according to the proportional hazards model relative to the hazard of the 
control non-GM feeding group. 90% confidence intervals for hazard ratios are indicated by 
error bars; when the lower limit is larger than 1 the one-sided null hypothesis is rejected. 
The hazard ratio is also given at the bottom of each bar. 
Figure 6 Mean hazard ratios for the overall GM versus non-GM control (red bars), for the 11% and 
33% GM inclusion rates (green bars), and for the GM feeds without Roundup (RU-) and 
with Roundup (RU+, blue bars). 
Figure 7 Percentage dead animals after 24 month in the 2-year cohort. 90% confidence intervals 
for the percentage are indicated by error bars. The percentage is also given at bottom of 
each bar. 
Figure 8 Residual variance for 4 points in time, expressed as a percentage of the historical 
reference residual variance. The red points are for the diffWBC measurements, which 
were only observed after 6  months, while the blue points are for the organ weights which 
were only observed after 12 months. 
Figure 9 Equivalence testing at 3 months of GM feeding groups versus the non-GM control feed for 
males. For estimates (square symbols) on the left of zero the GM feed has a smaller mean 
than the control feed. Endpoints labelled with a golden background have a large residual 
variance compared to the historical studies (VR>150%). Fuchsia coloured symbols denote 
a significant difference. 
Figure 10 Equivalence testing at 3 months of GM feeding groups versus the non-GM control feed for 
females. For estimates (square symbols) on the left of zero the GM feed has a smaller 
mean than the control feed. Endpoints labelled with a golden background have a large 
residual variance compared to the historical studies (VR>150%). Fuchsia coloured symbols 
denote a significant difference. 
Figure 11 Equivalence testing at 6 months of GM feeding groups versus the non-GM control feed for 
males. For estimates (square symbols) on the left of zero the GM feed has a smaller mean 
than the control feed. Endpoints labelled with a golden background have a large residual 
variance compared to the historical studies (VR>150%). Fuchsia coloured symbols denote 
a significant difference. 
G-TwYST Study A  Main statistical report 
61 
 
Figure 12 Equivalence testing at 6 months of GM feeding groups versus the non-GM control feed for 
females. For estimates (square symbols) on the left of zero the GM feed has a smaller 
mean than the control feed. Endpoints labelled with a golden background have a large 
residual variance compared to the historical studies (VR>150%). Fuchsia coloured symbols 
denote a significant difference. 
Figure 13 3 months data, 90% confidence intervals for the ratio of the mean of the GMO feed and 
the control feed for selected variables for males (left) and females (right), along with 
equivalence intervals defined by targeted effect sizes of Hong et al. (2017). 
Figure 14 6 months data, 90% confidence intervals for the ratio of the mean of the GMO feed and 
the control feed for selected variables for males (left) and females (right), along with 
equivalence intervals defined by targeted effect sizes of Hong et al. (2017). 
Figure 15 12 months data, 90% confidence intervals for the ratio of the mean of the GMO feed and 
the control feed for selected variables for males (left) and females (right), along with 
equivalence intervals defined by targeted effect sizes of Hong et al. (2017). 
Figure 16 24 months data, 90% confidence intervals for the ratio of the mean of the GMO feed and 
the control feed for selected variables for males (left) and females (right) that survived for 
24 months, along with equivalence intervals defined by targeted effect sizes of Hong et al. 
(2017). 
Figure 17 Classical approach to statistical analysis of data in long-term toxicity studies (copied from 
OECD 2012). 
Figure 18 Pairwise results for variables with set target effect sizes related to liver damage in Males 
after 12 months. In each row there are four graphs corresponding to the four GM feed 
groups. Points represent the ratio of the cage mean for the GM group vs. the cage mean 
for the control feed in ten blocks. Horizontal and vertical lines represent a ratio of 1 and 
the target effect sizes from Hong et al. (2017). 
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Appendix 1. Health status observations 
Animal Cage Sex Group Death Cens. Organ, sys. Finding Start End 
2 1 M NK33+ 347 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition 04-07-16 22-07-16 
21 11 M NK33+ 707 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition 23-01-17 17-07-17 
21   
   
skin mass- 1cm, lumbal area  23-01-17 17-07-17 
22 11 M NK33+ 728 1 skin mass- multiple, 1-5cm, axillary region 01-10-16 07-08-17 
23 12 M NK33+ 533 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea 06-12-16 24-01-17 
25 13 M NK33+ 728 1 skin 1. mass- lumbal area, 1,5cm  2.mass- axillary area, 2cm  08-07-17 07-08-17 
26 13 M NK33+ 682 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, torticollis, 
abnormal breathing 
24-04-17 23-06-17 
29 15 M NK33+ 693 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition 04-07-17 - 
32 16 M NK33+ 532 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition 03-01-17 24-01-17 
33 17 M NK33+ 352 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition 29-07-16 - 
34 17 M NK33+ 668 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, forelimbs 
cramps 
07-06-17 10-06-17 
36 18 M NK33+ 728 1 skin defect- 2,5cm in diamether, red coloured 27-07-17 09-08-17 
37 19 M NK33+ 532 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea 04-01-17 25-01-17 
39 20 M NK33+ 544 0 maxilla, nervous sys. weight loss, mass- left maxilla, 3cm in diameter 26-01-17 07-02-17 
40 20 M NK33+ 595 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, blepharospasmus 11-03-17 30-03-17 
41 21 M NK33+ 728 1 skin mass- 1cm, femoral area  chromodacryorrhea 27-07-17 10-08-17 
42 21 M NK33+ 728 1 skin mass- 1cm, thoracic area 26-01-17 00-08-17 
43 22 M NK33+ 474 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus 
16-11-16 29-11-16 
43 
     
skin mass- right thoracic area, 1cm in diamether 26-11-16 29-11-17 
44 22 M NK33+ 621 0 skin alopecia- symetric., abdominal area bilat., 4cm in diamether, round shaped  25-04-17 - 
46 23 M NK33+ 579 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture 
06-01-17 15-03-17 
47 24 M NK33+ 634 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture, cramps 
03-02-17 09-05-17 
48 24 M NK33+ 728 1 skin mass- 2cm, abdominal area 18-11-16 10-12-16 
49 25 M NK33+ 598 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture, cramps 
06-01-17 03-04-17 
53 27 M NK33+ 637 0 eye Right eye- enlargement, white coloured  weight loss 03-04-17 15-05-17 
55 28 M NK33+ 612 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture, eating bedding material, epistaxis 
11-03-17 21-04-17 
55 
     
skin mass- right mandible, 4-4,5cm 07-03-17 21-04-17 
57 29 M NK33+ 685 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, torticollis, paraplegia of hind limbs 
13-06-17 03-07-17 
G-TwYST Study A  Main statistical report appendices 
63 
 
58 29 M NK33+ 601 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, torticollis 
10-04-17 - 
61 31 M NK33+ 728 1 skin mass- multiple, 1-2cm 26-10-16 16-08-17 
63 32 M NK33+ 728 1 skin mass- mandible, 0,5cm 01-12-16 17-08-17 
66 33 M NK33+ 568 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, dyspnoe, abnormal 
vocalisation 
09-03-17 10-03-17 
66 
 
  
  
skin scrub- 3cm in diamether, lumbal area 08-03-16 30-07-16 
68 34 M NK33+ 644 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, torticollis 
26-05-17 - 
70 35 M NK33+ 687 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, torticollis 
30-06-17 08-07-17 
85 43 M NK11- 351 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus 
02-08-16 04-08-16 
92    
  
skin mass- 0,5cm, axillary area;  07-08-17 - 
97 49 M NK11- 546 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus 
04-02-17 07-02-17 
99 50 M NK11- 728 1 skin mass- inguinal area, 2cm 07-02-17 08-08-17 
101 51 M NK11- 245 0 spleen, liver weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, anemia, mass- abdominal cavity 
12-04-16 - 
107 54 M NK11- 728 1 skin/fur weight loss, alopecia in neck area bilateral symmetric 15-06-16 09-08-17 
113 57 M NK11- 417 0 nervous sys. weight loss, piloerection, lethargy 01-09-16 03-10-16 
117 59 M NK11- 728 1 skin cicatrix 28-08-16 11-08-17 
119 60 M NK11- 728 1 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus 
10-08-17 11-08-17 
120 60 M NK11- 728 1 skin mass- 7cm, abdominal area 27-07-17 11-08-17 
120    
  
nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus 
10-08-17 11-08-17 
129 65 M NK11- 728 1 head/ skin mass- 3 cm, temporal area 29-07-17 16-08-17 
130 65 M NK11- 728 1 head/ maxilla maloclusion- dentes incisivi 29-07-17 16-08-17 
130    
  
nervous sys. weight loss, piloerection, lethargy, poor overall condition 15-08-17 16-08-17 
133 67 M NK11- 615 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture 
11-03-17 26-04-17 
134 67 M NK11- 728 1 skin/fur alopecia- antebrachium, bilateral 12-02-17 17-08-17 
135 68 M NK11- 728 1 skin mass- shoulder blade area, 0,5 cm 26-11-16 17-08-17 
139 70 M NK11- 728 1 skin defect, scubs- head, pruritus 31-12-16 18-08-17 
145 73 M NK11+ 364 1 skin alopecia- axillary region, bilat, symetric, round shape, max 10-4cm, red coloured skin 09-02-16 10-08-16 
148 74 M NK11+ 231 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, blepharospasmus, hunched 
posture, dyspnoe, paraplegia of hind limbs 
30-03-16 31-03-16 
162 81 M NK11+ 728 1 skin mass- abdominal area, 2,5 cm 27-07-17 07-08-17 
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164 82 M NK11+ 621 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition 10-04-17 22-04-17 
167 84 M NK11+ 728 1 skin mass- scapular area, 0,5 cm 05-07-16 26-11-16 
167    
  
skin mass- lumbal area, 1,5cm 27-07-17 08-08-17 
169 85 M NK11+ 450 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture 
11-10-16 03-11-16 
172 86 M NK11+ 476 0 skin tail- defect, scub, bleeding 25-10-16 29-11-16 
178 89 M NK11+ 449 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture 
26-10-16 03-11-16 
179 90 M NK11+ 683 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, hunched posture 20-06-17 26-06-17 
181 91 M NK11+ 704 0 head/skin mass- 6cm, frontal area 07-07-17 17-07-17 
187 94 M NK11+ 565 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture 
03-02-17 01-03-17 
188 94 M NK11+ 728 1 abdominal cavity mass- in abdominal cavity, 12cm, abdominalgy 23-06-17 11-08-17 
190 95 M NK11+ 728 1 skin mass- abdominal area, 1cm, green coloured 23-12-16 11-03-17 
190    
  
skin red coloured skin, scubs - tail, scrotum 04-02-17 11-08-17 
190    
  
eye white coloured, bilateral 27-07-17 11-08-17 
195 98 M NK11+ 651 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture 
16-05-17 30-05-17 
199 100 M NK11+ 182 0 nervous sys. paraplegia- hind limbs 15-02-16 17-02-16 
205 103 M NK11+ 562 0 skin scub- lumbal area, 2cm 08-03-16 30-07-16 
209 105 M NK11+ 460 0 nervous sys. piloerection, lethargy, poor overall condition 23-11-16 - 
212 106 M NK33- 364 1 back area alopecia- 0,5x0,4 cm 12-03-16 29-04-16 
214 107 M NK33- 364 1 back area bite wound 20-10-15 -10-2015 
216 108 M NK33- 364 1 ear lobe scub 17-02-16 12-03-16 
227 114 M NK33- 364 1 skin scub- 2cm, round shape, lumbal area 08-03-16 30-07-16 
233 117 M NK33- 536 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, hunched posture 23-01-17 27-01-17 
235 118 M NK33- 728 1 tail biteing off tail 22-05-17 07-08-17 
236 118 M NK33- 575 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, dyspnoe, 
hunched posture 
07-03-17 - 
238 119 M NK33- 492 0 head- bones mass- bleeding, scub,putrefactive odour, 3cm; anemia, piloerection, hunched posture 14-08-16 15-12-16 
239 120 M NK33- 542 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, dyspnoe, 
hunched posture 
11-10-16 03-02-17 
240 120 M NK33- 728 1 skin/mammary gl. mass- abdominal area, 3cm 27-05-17 08-08-17 
245 123 M NK33- 574 0 skin/fur alopecia-bilatereral, symetric, neck area 04-11-15 30-07-16 
246 123 M NK33- 728 1 skin mass/ scub- abdominal area 19-07-17 09-08-17 
247 124 M NK33- 707 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, dyspnoe, 
hunched posture 
21-06-17 19-07-17 
250 125 M NK33- 728 1 praeputial lymphno. left- enlargement 09-08-17 10-08-17 
251 126 M NK33- 616 0 skin mass- abdominal area, 7cm, bleeding 09-03-17 20-04-17 
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253 127 M NK33- 728 1 skin mass- femoral area, 2cm 11-03-17 10-08-17 
254 127 M NK33- 728 1 skin mass- shoulder blade area, 1 cm 01-04-17 10-08-17 
255 128 M NK33- 728 1 skin mass- multiple, 0,5cm, lumbal and inguinal area 21-01-17 11-08-17 
256 128 M NK33- 728 1 skin mass- lumbal area, 0,5cm, green 23-11-16 04-02-17 
258 129 M NK33- 724 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture, aggressive behavior 
01-10-16 07-08-17 
259 130 M NK33- 728 1 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture, blind, tremor 
10-08-17 - 
263 132 M NK33- 498 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, dyspnoe, 
hunched posture 
18-12-16 27-12-16 
269 135 M NK33- 401 0 eye enargement, bleeding,  12-09-16 23-09-16 
273 137 M NK33- 695 0 skin mass- 1cm, lumbal area  01-04-17 15-07-17 
284 142 M Control 364 1 skin/mammary gl. mass- 1,5-2cm, inguinal area 02-06-16 09-06-16 
297 149 M Control 364 1 skin scub- left masseter area -10-2015 -11-2015 
304 152 M Control 604 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture 
13-01-00 05-04-17 
309 155 M Control 583 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture 
16-03-17 - 
315 158 M Control 728 1 skin mass- left shoulder blade area, red; bleeding, musous membranes anemia 31-12-16 09-08-17 
316 158 M Control 598 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus 
01-03-17 01-04-17 
319 160 M Control 490 0 skin mass- inguinal area, 2,5cm, scub, 29-09-16 15-12-16 
319    
  
skin mass- thoracic area, 4cm, algecis;  polydipsia, hunched posture 10-12-16 15-12-16 
320 160 M Control 728 1 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture, blind, tremor 
27-07-17 10-08-17 
324 162 M Control 516 0 skin scubs, multiple 24-06-16 10-01-17 
324    
  
skin mass- 10cm, black coloured, abdominal area 06-11-16 10-01-17 
326 163 M Control 669 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus 
07-10-16 13-06-17 
327 164 M Control 728 1 head- masseter 
muscle 
mass- 3cm, bleeding, scub; weight loss 18-12-16 11-08-17 
329 165 M Control 728 1 skin scub- frontal area 22-07-16 11-08-17 
332 166 M Control 496 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea 08-12-16 21-12-16 
340 170 M Control 518 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea 14-12-16 18-01-17 
343 172 M Control 637 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, anemia, 
hunched posture, blepharospasmus 
23-02-17 18-05-17 
345 173 M Control 728 1 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, 
blepharospasmus, hunched posture 
16-08-17 17-08-17 
347 174 M Control 500 0 maxilla mass- 2cm, white- yellow, putrefactive odour,  chromodacryorrhea, weight loss 18-11-16  2-01-17 
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Animal Cage Sex Group Death Cens. Organ, sys. Finding Start End 
506 503 F NK33+ 364 1 tail skin- red, scubs, necrosis, biteing of tail, anemia, poor overall condition, hunched 
posture, piloerection 
29-06-16 24-08-16 
521 511 F NK33+ 728 1 fur whole body- alopecia 29-01-16 21-08-17 
521    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
21-08-17 - 
522 511 F NK33+ 667 0 skin/mammary gl. mass- multiple, 2cm 10-04-17 21-06-17 
523 512 F NK33+ 613 0 skin/mammary gl. mass- 5cm, algesic, dark red; lethargy 25-03-17 22-04-17 
528 514 F NK33+ 728 1 fur alopecia- bilateral symmetric, forelimbs 23-02-16 22-08-17 
531 516 F NK33+ 728 1 skin/mammary gl. mass- 4cm 21-08-17 22-08-17 
532 516 F NK33+ 663 0 skin/mammary gl. mass- caudal part of mammary gland, 9ccm, bleeding, dark red 12-12-16 18-06-17 
535 518 F NK33+ 728 1 skin/mammary gl. mass- 2-3cm, inguina 08-02-17 23-08-17 
535    
  
skin mandible- 0,4cm 30-07-17 23-08-17 
536 518 F NK33+ 728 1 skin/mammary gl. mass- 7-9cm, dark red skin 01-04-17 23-08-17 
537 519 F NK33+ 704 0 fur alopecia- sternum  28-07-16 04-09-16 
537     
 
nervous sys. weight loss, lethargy 30-07-17 - 
540 520 F NK33+ 728 1 reproductive sys. mass- vulvar area, 2,5cm 27-07-17 24-08-17 
541    
  
skin/mammary gl. mass- inguina, 2cm 30-07-17 24-08-17 
543 522 F NK33+ 551 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, hunched 
posture 
20-01-17 28-02-17 
544 522 F NK33+ 728 1 skin wounds, scubs- neck, lumbal area 30-06-16 24-08-17 
545 523 F NK33+ 728 1 skin/mammary gl. mass- 1cm 24-08-17 25-08-17 
546 523 F NK33+ 599 0 skin/mammary gl. mass- 5cm, caudal part of mammary gland, dark red- black, anemic, hunched posture, 
poor overall condition 
26-11-16 18-04-17 
547 524 F NK33+ 728 1 eye enlargement, torticollis 30-07-17 25-08-17 
548 524 F NK33+ 728 1 skin/mammary gl. mass- caudal part of mammary gland, 4cm, bleeding 30-07-17 25-08-17 
549 525 F NK33+ 728 1 skin/mammary gl. mass- axilla, 4cm 24-08-17 25-08-17 
554 527 F NK33+ 562 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, hunched 
posture 
22-02-17 15-03-17 
555 528 F NK33+ 552 0 fur alopecia- femoral area, 3cm 31-12-16 06-03-17 
555    
  
nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, hunched 
posture 
21-02-17 06-03-17 
556 528 F NK33+ 524 0 fur alopecia- 2cm, neck 02-10-13 06-02-17 
556    
  
skin/mammary gl. mass- multiple, 3-7cm, dark red-black, bleeding 22-11-16 06-02-17 
557 529 F NK33+ 596 0 nervous sys. weight loss, chromodacryorrhea 10-04-17 19-04-17 
558 529 F NK33+ 728 1 skin/mammary gl. mass- muiltiple, 4cm 30-07-17 05-09-17 
559 530 F NK33+ 728 1 skin/mammary gl. mass- multiple, axilla, inguina, 3-4 cm 28-02-17 06-09-17 
560 530 F NK33+ 728 1 skin mass- neck, 4 cm, dark red 27-05-17 06-09-17 
561 531 F NK33+ 713 0 fur alopecia- forelimbs, hindlimbs- bilateral symetric 23-09-15 12-03-16 
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561    
  
eye left- exophtalmus, enlargement, defect, bleeding 30-07-17 07-08-17 
562 531 F NK33+ 561 0 fur alopecia- neck- bilateral, symetric 23-09-15 16-03-17 
562    
  
skin/mammary gl. mass- inguina, 4 cm, bleeding, open wound 06-11-16 16-03-17 
562    
  
nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, hunched 
posture, anemia 
04-02-17 16-03-17 
563 532 F NK33+ 434 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, hunched 
posture 
10-11-16 - 
568 534 F NK33+ 728 1 skin/mammary gl. mass- 1,5cm 07-09-17 08-09-17 
569 535 F NK33+ 728 1 skin mass- axilla, 1,5cm 07-09-17 08-09-17 
570 535 F NK33+ 504 0 nervous sys. weight loss, piloerection, lethargy, poor overall condition, chromodacryorrhea, hunched 
posture 
25-11-16 20-01-17 
579 540 F NK11- 364 1 skin wound- 1cm, lumbal area 06-07-16 28-07-16 
583 542 F NK11- 364 1 maxilla, incisors maloclusion- overgrown upper incisors 06-11-15 06-09-16 
585 543 F NK11- 364 1 skin mass- inguina, 3cm 29-06-16 07-09-16 
591 546 F NK11- 728 1 mandibular 
lymphnodes 
enlargement 30-07-17 21-08-17 
592 546 F NK11- 728 1 skin/mammary gl. mass- multiple, 3-8cm, dark red skin 10-04-17 21-08-17 
593 547 F NK11- 613 0 eye exophtalmus, torticollis 04-12-16 28-04-17 
593    
  
skin/mammary gl. mass- 4cm, bleeding, open wound, anemia 11-03-17 28-04-17 
595 548 F NK11- 701 0 skin/mammary gl. mass- multiple, 1-4cm 20-06-16 25-07-17 
595    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
25-07-17 - 
596 548 F NK11- 679 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
03-07-17 - 
597 549 F NK11- 526 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, torticollis 
01-02-17 - 
598 549 F NK11- 619 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, torticollis 
03-05-17  5-05-17 
599 550 F NK11- 616 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition 28-03-17 02-05-17 
603 552 F NK11- 728 1 skin/mammary gl. mass-caudal part, 7cm, black coloured skin 21-06-17 23-08-17 
605 553 F NK11- 728 1 skin/mammary gl. mass- 5cm, caudal part of mammary gland 21-06-17 23-08-17 
606 553 F NK11- 650 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
17-05-17 06-06-17 
606    
  
skin/mammary gl. mass- 6cm, dark red skin 28-01-00 23-08-17 
608 554 F NK11- 657 0 skin/mammary gl. mass- axilla, 5cm, black, open wound 09,11,16 13-06-17 
609 555 F NK11- 403 0 skin/mammary gl. mass- axilla, 12cm, poor body condition 14-07-16 03-10-16 
611 556 F NK11- 651 0 skin scubs- multiple, shoulder blade area and head 04-02-17 01-04-17 
611    
  
skin/mammary gl. mass- neck, 2cm 18-05-17 08-06-17 
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612 556 F NK11- 670 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, torticollis 
27-05-17 27-06-17 
613 557 F NK11- 323 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
14-07-16 15-07-16 
614 557 F NK11- 728 1 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
23-08-17 24-08-17 
615 558 F NK11- 669 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
20-06-17 27-06-17 
616 558 F NK11- 372 0 skin/fur whole body- alopecia, red coloured skin, scubs, conjuctivitis 01-01-16 03-09-16 
617 559 F NK11- 728 1 skin/mammary gl. mass- 2cm 24-08-17 25-08-17 
618 559 F NK11- 728 1 skin/mammary gl. mass- multiple, 1-2cm 04-02-17 25-08-17 
619 560 F NK11- 728 1 skin/mammary gl. mass- inguina, 4cm 30-07-17 25-08-17 
620 560 F NK11- 707 0 skin/mammary gl. mass- 5cm 30-07-17 04-08-17 
620    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
30-07-17 04-08-17 
621 561 F NK11- 646 0 skin/mammary gl. mass- 12x10cm, dark red, poor body condition 26-11-16 07-06-17 
622 561 F NK11- 728 1 skin/mammary gl. mass- axilla, 1,5cm 04-09-17 - 
624 562 F NK11- 728 1 nervous sys. torticollis 04-09-17 - 
624    
  
skin/mammary gl. mass- 5cm, dark red skin 04-09-17 - 
627 564 F NK11- 694 0 skin/mammary gl. mass- 10 cm, open wound, bleeding, putrefactive odour 31-12-16 26-07-17 
628 564 F NK11- 647 0 skin/mammary gl. mass- 2,5cm, caudal part 04-02-17 09-06-17 
628    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
01-06-17 09-06-17 
629 565 F NK11- 728 1 skin mass- lumbal area, 1cm;  epistaxis 30-07-17 06-09-17 
632 566 F NK11- 238 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
20-04-16 27-04-16 
633 567 F NK11- 420 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
10-10-16 27-10-16 
636 568 F NK11- 617 0 skin/mammary gl. mass- multiple, 4-7cm, poor body condition, hunched posture 07-04-16 12-05-17 
638 569 F NK11- 728 1 skin mass- shoulder blade area, 3 cm, bleeding, defect, open wound 09-20016 08-09-17 
640 570 F NK11- 728 1 skin/mammary gl. mass- 4cm, abdominal area 07-09-17 08-09-17 
661 581 F NK11+ 728 1 skin/mammary gl. mass- inguina, 3cm 21-08-17 - 
662 581 F NK11+ 728 1 skin/mammary gl. mass-2,5cm, axilla 21-08-17 - 
663 582 F NK11+ 728 1 skin/mammary gl. mass- 6-7cm, multiple scubs  10-12-16 21-08-17 
664 582 F NK11+ 728 1 skin/mammary gl. mass- 3cm, black skin, bleeding, anemia, poor body condition, hunched posture 17-04-17 21-08-17 
665 583 F NK11+ 650 0 skin/mammary gl. mass- 8x6cm, dark red- black, poor body condition 10-01-17 04-06-17 
669 585 F NK11+ 707 0 skin scubs- lumbal area, 4cm 15-09-16 06-11-16 
669    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
01-08-17 - 
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670 585 F NK11+ 728 1 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, dyspnoe, epistaxis,anemia 
11-03-17 22-08-17 
671 586 F NK11+ 728 1 skin, fur, eye whole body- alopecia, red coloured skin, scubs, conjuctivitis 28-01-16 22-08-17 
672 586 F NK11+ 587 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
28-03-17 03-04-17 
673 587 F NK11+ 513 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
21-12-16 20-01-17 
674 587 F NK11+ 704 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
29-07-17 30-07-17 
675 588 F NK11+ 728 1 skin/mammary gl. mass- multiple, 0,5-1cm 22-08-17 23-08-17 
676 588 F NK11+ 592 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
29-03-17 09-04-17 
677 589 F NK11+ 506 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
18-12-16 13-01-17 
678    
  
skin/mammary gl. mass- inguina,3cm 30-07-17 23-08-17 
679 590 F NK11+ 594 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, epistaxis 
19-01-17 12-04-17 
680 590 F NK11+ 454 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, epistaxis 
29-09-16 23-11-16 
681 591 F NK11+ 656 0 skin/mammary gl. mass- 5-6cm, dark red, open wound, anemia 26-01-17 13-06-17 
683 592 F NK11+ 434 0 mammary gl. mass- 6-8cm, green scubs on skin, algesic 29-09-16 03-11-16 
685 593 F NK11+ 616 0 skin/mammary gl. mass- 1cm, dark red, scub 02-04-17 05-05-17 
685    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, tremor 
02-04-17 05-05-17 
687 594 F NK11+ 728 1 skin wounds, scubs- multiple, lumbal area 30-12-15 25-08-17 
690 595 F NK11+ 728 1 skin/mammary gl. mass- inguina, 10cm, dark red skin 15-07-17 25-08-17 
691 596 F NK11+ 701 0 skin/mammary gl. mass- axilla, 3 cm  20-02-17 01-08-17 
691    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, epistaxis 
30-07-17 01-08-17 
692 596 F NK11+ 658 0 skin/mammary gl. mass- 2,5cm, caudal part 20-06-16 19-06-17 
692    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
28-05-17 19-06-17 
693 597 F NK11+ 610 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
02-04-17 02-05-17 
694 597 F NK11+ 728 1 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, vaginal secretion- green 
04-09-17 - 
695 598 F NK11+ 728 1 skin/mammary gl. mass- inguina, 5cm 20-08-17 05-09-17 
696 598 F NK11+ 694 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
05-05-17 26-07-17 
G-TwYST Study A  Main statistical report appendices 
70 
 
697 599 F NK11+ 615 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
05-05-17 08-05-17 
698    
  
skin/mammary gl. mass- 1cm 04-09-17 05-09-17 
699 600 F NK11+ 728 1 skin/mammary gl. mass- multiple, 3-6cm 28-05-17 06-09-17 
703 602 F NK11+ 728 1 skin scubs- multiple, lumbal area and head 15-03-16 07-09-17 
705 603 F NK11+ 728 1 skin/mammary gl. mass- axilla, 1,5cm 06-09-17 07-09-17 
707 604 F NK11+ 704 0 skin/mammary gl. mass- 2cm, caudal part, open wound 30-07-17 08-08-17 
707    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition 08-08-17 - 
709 605 F NK11+ 728 1 vulva mass- dark red, bleeding, anemia 30-07-17 08-09-17 
714 607 F NK33- 364 1 auricle scubs, red coloured 25-02-16 12-03-16 
727 614 F NK33- 364 1 skin wounds, scubs- thoracic area 01-10-15 08-09-16 
730 615 F NK33- 364 1 skin wound- 0,5cm 09-03-16 29-04-16 
731 616 F NK33- 576 0 skin/mammary gl. mass- 12cm, inguina, dark coloured skin, open wound 23-08-16 22-03-17 
732 616 F NK33- 466 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, abdominalgy 
31-10-16 02-12-16 
733 617 F NK33- 688 0 fur alopecia-hind limbs, lumbal area -12-2015 12-07-17 
733    
  
skin/mammary gl. mass- multiple, 1-3cm 06-11-16 12-07-17 
733    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
07-07-17 12-07-17 
734 617 F NK33- 728 1 fur alopecia- frontal area 14-12-15 21-08-17 
735 618 F NK33- 728 1 fur alopecia- neck area, shoulder blade area- bilateral symetric 19-10-15 21-08-17 
735    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
21-08-17 - 
737 619 F NK33- 728 1 skin scubs, wounds 23-09-15 22-08-17 
737    
  
skin/mammary gl. mass- multiple, 1-2,5cm, bleeding 02-04-17 22-08-17 
738 619 F NK33- 637 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
23-05-17 - 
740 620 F NK33- 728 1 skin/mammary gl. mass- 4-5cm, red skin 28-05-17 22-08-17 
741 621 F NK33- 721 0 skin/mammary gl. mass- 2,5cm, axilla 25-03-17 15-08-17 
741    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
30-07-17 15-08-17 
742 621 F NK33- 653 0 skin/mammary gl. mass- 2,5cm, cranial part of mammary gland 31-01-17 08-06-17 
742    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
28-05-17 08-06-17 
744 622 F NK33- 728 1 skin/mammary gl. mass- multiple, 2-3 cm 04-02-17 23-08-17 
744     
 
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea, torticollis 
22-08-17 23-08-17 
745 623 F NK33- 299 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
15-06-16 20-06-16 
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749 625 F NK33- 662 0 skin/mammary gl. mass- 4-5cm, axilla, dark red skin 18-05-17 19-06-17 
751 626 F NK33- 728 1 skin/mammary gl. mass- multiple, axilla, 2-4 cm 023-08- 24-01-00 
752 626 F NK33- 663 0 skin/mammary gl. mass- 4-5cm, caudal part 01-06-17 10-06-17 
752    
  
nervous sys. weight loss , piloerection, lethargy, hunched posture, chromodacryorrhea, torticollis 10-06-17 20-06-17 
755 628 F NK33- 630 0 skin/mammary gl. mass- multiple, 2-3cm 21-01-17 19-05-17 
755    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
19-05-17 - 
757 629 F NK33- 573 0 head mass- 4cm, dental maloclusion, weight loss  13-01-17 23-03-17 
758 629 F NK33- 728 1 skin/mammary gl. mass- axilla, 1,5cm 25-08-17 - 
759 630 F NK33- 681 0 skin/mammary gl. mass- 3cm, shoulder blade area 09-06-17 09-07-17 
759    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
07-07-17 09-07-17 
760 630 F NK33- 609 0 skin/mammary gl. mass- caudal part, 2cm,  15-07-16 28-04-17 
760    
  
nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
28-04-17 - 
761 631 F NK33- 728 1 eye chromodacryorrhea 14-15-15 04-09-17 
761    
  
skin/mammary gl. mass- 3cm, axilla; tremor 10-04-17 04-09-17 
762 631 F NK33- 728 1 eye chromodacryorrhea 21-11-15 04-09-17 
763 632 F NK33- 728 1 reproductive sys. vaginal bleeding, anemia 28-05-17 04-09-17 
764 632 F NK33- 616 0 skin/mammary gl. mass- axilla, 6 cm, bleeding 12-03-17 08-05-17 
765 633 F NK33- 619 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
18-04-17 12-05-17 
766 633 F NK33- 728 1 auricle scub- bilateral 28-09-16 10-12-16 
767 634 F NK33- 728 1 skin/mammary gl. mass- cranial part of mammary gl., 0,5cm 04-09-17 05-09-17 
773 637 F NK33- 728 1 skin/mammary gl. mass- multiple, 3-6cm 26-01-17 07-09-17 
775 638 F NK33- 552 0 fur alopecia- sternal area 28-07-16 08-03-17 
776 638 F NK33- 581 0 fur alopecia- head, unilat. 02-04-16 - 
776    
  
nervous sys. piloerection, lethargy, hunched posture 06-04-17 - 
778 639 F NK33- 683 0 skin/mammary gl. mass- multiple, 2-5cm, open wound, dark coloured 26-11-16 18-07-17 
779 640 F NK33- 728 1 skin/mammary gl. mass- axilla, 2,5 cm 07-09-17 08-09-17 
780 640 F NK33- 728 1 skin/mammary gl. mass- inguina, 4cm 04-09-17 08-09-17 
784 642 F Control 364 1 auricle scubs, red coloured 28-02-16 12-03-16 
790 645 F Control 364 1 skin wounds, scubs- lumbal area 15-07-16 26-08-16 
792 646 F Control 364 1 skin/mammary gl. mass- 6cm, caudal part of mammary gland 01-08-16 05-09-16 
798 649 F Control 364 1 skin tail- bite wounds 28-07-16 21-08-16 
801 651 F Control 728 1 skin/mammary gl. mass- axilla, 1,5cm 21-08-17 - 
802 651 F Control 666 0 skin/mammary gl. mass- multiple, 2-4cm 06-11-16 20-06-17 
802    
  
nervous sys. piloerection, hunched posture 20-06-17 - 
802    
  
fur alopecia- 5-6cm, unilat. 05-02-17 20-06-17 
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804 652 F Control 332 0 skin/fur scubs/ wound- lumbal area, 5cm, weight loss, poor body condition 17-10-15 21-07-16 
805 653 F Control 418 0 skin/mammary gl. mass- 1cm, caudal part 30-07-16 15-10-16 
806 653 F Control 420 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
10-10-16 17-10-16 
808 654 F Control 476 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
13-12-16 - 
809 655 F Control 589 0 skin/mammary gl. mass- 5cm, axilla, dark red, poor overall condition 21-01-17 05-04-17 
813 657 F Control 394 0 nervous sys. piloerection, lethargy, poor overall condition, hunched posture 23-09-16 - 
814 657 F Control 609 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
26-04-17 - 
814    
  
skin/mammary gl. mass- 5cm, dark coloured skin 28-02-17 26-04-17 
817 659 F Control 506 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea,  
17-12-16 13-01-17 
820 660 F Control 728 1 skin/mammary gl. mass- axilla, 3cm 30-07-17 24-08-17 
823 662 F Control 728 1 skin/mammary gl. mass- multiple, axilla, inguina, 2-2,5cm 30-07-17 24-08-17 
824 662 F Control 728 1 mammary gl. mass- 5cm 30-07-17 24-08-17 
826 663 F Control 537 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
03-02-17 15-02-17 
826    
  
skin/mammary gl. mass- 5cm, axilla, dark red coloured 21-08-16 15-02-17 
828 664 F Control 728 1 skin/mammary gl. mass- inguina, 2cm 30-07-17 25-08-17 
830 665 F Control 629 0 nervous sys. weight loss , piloerection, lethargy, poor overall condition, hunched posture, 
chromodacryorrhea 
18-05-17 - 
831    
  
skin/mammary gl. mass- multiple, 4-7cm, porr body condition, hunched posture 30-07-17 04-09-17 
832 666 F Control 654 0 skin/mammary gl. mass- 5-7cm 20-02-17 15-06-17 
833 667 F Control 728 1 skin/mammary gl. mass- axilla, 4-5cm 20-03-17 04-09-17 
834 667 F Control 728 1 skin/mammary gl. mass- inguina, 1cm, poor body condotion, hunched posture 30-07-17 04-09-17 
835 668 F Control 528 0 skin/mammary gl. mass- 10cm, dark coloured skin, axilla,  02-08-16 10-02-17 
836 668 F Control 728 1 skin/mammary gl. mass- dark coloured, 2cm 30-07-17 05-09-17 
837 669 F Control 728 1 skin/mammary gl. mass- dark red, 1cm 04-09-17 05-09-17 
838 669 F Control 728 1 skin/mammary gl. mass- multiple, 6cm, bleeding, open wound;  poor overall condition 05-02-17 05-09-17 
840 670 F Control 454 0 skin/mammary gl. mass- 9cm, dark coloured, scub 30-07-16 29-11-16 
841 671 F Control 523 0 skin-tail mass- 4-5cm, bleeding 11-05-16 06-02-17 
841    
  
lymph.nodes inguinal lymphn.- enlargement bilat. 31-12-16 06-02-17 
842 671 F Control 532 0 skin/mammary gl. mass- 10-12cm, dark coloured skin, poor body condition 25-09-16 15-02-17 
843 672 F Control 445 0 skin scubs/wounds- lumbal area, 8x8cm area, poor body condition, weight loss 04-01-16 21-11-16 
845 673 F Control 728 1 fur alopecia- bilateral symmetric, auricle area 18-05-17 07-09-17 
847 674 F Control 728 1 skin/mammary gl. mass- axilla, 4cm 07-09-17 08-09-17 
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Appendix 2. Sums of squares, degrees of freedom and effective replication for the 
GRACE data 
The values below are based on a simultaneous statistical analysis of the five GRACE studies A-E on 
cage means after a log-transform and after removal of outliers. The columns have the following 
interpretation: 
• 𝑆𝑆𝑆𝑆𝑅𝑅  the between reference feeds sums of squares 
• 𝑆𝑆𝑆𝑆𝐸𝐸  the residual sums of squares 
• 𝑑𝑑𝑓𝑓𝐸𝐸  the degrees of freedom for the residual sums of squares 
• 𝑖𝑖𝑊𝑊𝑒𝑒𝑒𝑒  the effective replication 
• %R/S  the between reference feeds estimated standard error (𝜎𝜎𝑅𝑅) as a percentage of the 
estimated residual standard error (𝜎𝜎𝐸𝐸), where empty cells denote zero values. 
Variable Male rats Female rats 
𝑆𝑆𝑆𝑆𝑅𝑅  𝑆𝑆𝑆𝑆𝐸𝐸  𝑑𝑑𝑓𝑓𝐸𝐸  𝑖𝑖𝑊𝑊𝑒𝑒𝑒𝑒 %R/S 𝑆𝑆𝑆𝑆𝑅𝑅  𝑆𝑆𝑆𝑆𝐸𝐸  𝑑𝑑𝑓𝑓𝐸𝐸  𝑖𝑖𝑊𝑊𝑒𝑒𝑒𝑒 %R/S 
BodyWeight 0.008387 0.19554 69 10.50  0.014574 0.26913 69 10.50  
growthRate 0.000206 0.02434 68 10.33  0.000751 0.06011 69 10.50  
FeedMean 0.022190 0.16515 69 10.50 35 0.032193 0.24197 69 10.50 35 
WBC 0.489441 2.61275 59 9.25 44 0.356101 3.36561 59 9.25 25 
RBC 0.004304 0.14638 59 9.25 
 
0.007652 0.07286 59 9.25 24 
HGB 0.008819 0.09808 58 9.08 18 0.003452 0.05478 59 9.25 
 
HCT 0.005987 0.13627 59 9.25  0.004400 0.04452 59 9.25 22 
MCV 0.000242 0.01864 59 9.25  0.000925 0.02226 59 9.25  
MCH 0.001610 0.03980 58 9.08  0.002266 0.05291 58 9.11  
MCHC 0.001347 0.01505 58 9.08 18 0.000187 0.01436 57 8.94  
PLT 0.056905 3.74573 59 9.25 
 
0.057845 1.66444 57 9.08  
LYMA 0.402469 2.53641 59 9.25 38 0.320270 3.15442 59 9.25 23 
Lymphocytes 0.008561 0.11920 59 9.25 8 0.012897 0.12741 59 9.25 23 
Neutrophils 0.101555 1.54710 59 9.25 
 
0.214056 1.72788 59 9.25 30 
Monocytes 0.932225 6.25457 59 9.25 36 0.948050 4.73942 59 9.25 46 
Eosinophils 1.831756 12.92053 59 9.25 34 1.006901 14.28882 59 9.25 7 
ALP 0.058075 1.80285 59 9.25  0.050742 1.41079 59 9.25  
ALT 0.040433 0.76309 57 8.90  0.143187 3.83379 59 9.25  
AST 0.082408 1.33797 58 9.08  0.108613 2.28004 58 9.08  
ALB 0.003719 0.16461 58 9.08  0.002401 0.49386 59 9.25  
TP 0.003316 0.09254 59 9.25  0.044110 0.30963 59 9.25 35 
Glu 0.137923 1.20832 59 9.25 27 0.068248 1.26028 58 9.08 
 
CHOL 0.157821 0.72566 59 9.25 49 0.066835 0.91290 59 9.25 9 
TAG 1.512480 4.78566 59 9.25 63 0.455467 6.38891 59 9.25 7 
Crea 0.100802 1.01337 59 9.25 22 0.169402 0.84663 59 9.25 46 
Urea 0.162169 0.56082 59 9.25 59 0.212305 0.68252 59 9.25 62 
Ca 0.021413 0.21007 58 9.25 23 0.069969 0.13967 58 9.08 83 
Cl 0.010708 0.13568 59 9.25 13 0.001771 0.04791 59 9.25 
 
K 0.025453 0.68615 59 9.25 
 
0.063943 0.62498 58 9.08 23 
Na 0.011611 0.16216 59 9.25 8 0.003438 0.04081 58 9.08 16 
P 0.071064 0.54837 58 9.08 31 0.084107 0.93345 59 9.25 19 
  
G-TwYST Study A  Main statistical report appendices 
75 
 
Variable Male rats Female rats 
𝑆𝑆𝑆𝑆𝑅𝑅  𝑆𝑆𝑆𝑆𝐸𝐸  𝑑𝑑𝑓𝑓𝐸𝐸  𝑖𝑖𝑊𝑊𝑒𝑒𝑒𝑒 %R/S 𝑆𝑆𝑆𝑆𝑅𝑅  𝑆𝑆𝑆𝑆𝐸𝐸  𝑑𝑑𝑓𝑓𝐸𝐸  𝑖𝑖𝑊𝑊𝑒𝑒𝑒𝑒 %R/S 
Kidney 0.008755 0.15764 50 8.00  0.002113 0.14971 50 8.00  
Spleen 0.028870 0.32638 50 8.00 11 0.007828 0.48420 50 8.00  
Liver 0.011485 0.10964 48 7.66 18 0.021902 0.24719 50 8.00 12 
AdrenGl 0.054960 0.63981 50 8.00 10 0.021734 0.71168 50 8.00  
Heart 0.015268 0.12327 50 8.00 26 0.005002 0.16094 50 8.00  
Thymus 0.135724 1.59675 50 8.00 9 0.168167 0.75330 50 8.00 47 
Testis 0.012233 0.26694 50 8.00  - - - -  
Epididymis 0.012314 0.28836 50 8.00  - - - -  
Uterus - - - -  0.063741 1.37482 49 7.83  
Ovary - - - -  0.187232 0.81620 50 8.00 48 
Brain 0.017742 0.11613 50 8.00 34 0.012478 0.19660 50 8.00  
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Appendix 3. R-script for the classical statistical analysis. 
# Classical Statistical analysis of a single response for G-TwYST studies  
# Define some settings 
alpha <- 0.95            # Confidence level for intervals 
friedman.mc <- 20000     # Number of MC samples for p.value of Friedman test 
friedman.limit <- 0.25   # Do MC when Asymptotic p.value is smaller than limit 
set.seed(492193917)      # Initialize random generator 
alpha2 <- (1+alpha)/2 
 
# Define a dataframe to save results of test-statistics 
testStats <- as.data.frame(matrix(nrow=9,ncol=2)) 
colnames(testStats) <- c("statistic", "value") 
rownames(testStats) <- c("fAnova", "pAnova", "pKS", "pSW",  
    "pFriedmanAs", "pFriedmanMc","pBartlett", "pLeveneMean", "pLeveneMedian") 
testStats[,1] <- c("fAnova", "pAnova", "pKS", "pSW",  
    "pFriedmanAs", "pFriedmanMc","pBartlett", "pLeveneMean", "pLeveneMedian") 
 
# Get data, define factors and sort (necessary for wilcox.test()) 
data <- read.csv("RscriptInput.csv") 
data$block <- as.factor(data$block) 
data$treat <- as.factor(data$treat) 
newlevels <- levels(data$treat)[c(1,2,4,3,5)] 
data$treat <- factor(data$treat, newlevels) 
data <- data[order(data$block, data$treat),] 
 
# Load libraries  
suppressMessages(library(multcomp))  # For Dunnett multiple comparison after ANOVA 
suppressMessages(library(MBESS))     # For SES intervals 
suppressMessages(library(NSM3))      # For p.value of non-parametric Friedman test 
suppressMessages(library(car))       # For Levene test for homogeneity of variance 
library(broom)                       # For the tidy() function 
 
# ================================================================================= 
# Randomized block ANOVA; note that lm() takes proper account of any unbalance 
# Estimates for treat are differences between GMO feeds and the Control feed 
# ================================================================================= 
lm0 <- lm(response ~ block, data) 
lm  <- lm(response ~ block + treat, data) 
aov <- anova(lm, lm0) 
testStats["fAnova","value"] <- aov$F[2] 
testStats["pAnova","value"] <- aov$'Pr(>F)'[2] 
estimates <- tidy(lm) 
estimates 
 
# Extract results for treatment differences, rename columns, add Residual Df and Se 
tAnova <- estimates[startsWith(estimates[,1],"treat"),  
    c("term", "estimate", "std.error", "statistic", "p.value")] 
colnames(tAnova)[c(3,4,5)] <- c("se", "tvalue", "pvalue") 
tAnova$term <- gsub("treat", "", tAnova$term) 
tAnova$term <- gsub("'", "", tAnova$term) 
tAnova$dfRes <- df.residual(lm) 
tAnova$seRes <- summary(lm)$sigma 
 
# Add confidence interval for differences 
edt <- qt(alpha2, tAnova$dfRes) 
tAnova$CIlower <- tAnova$estimate - edt*tAnova$se 
tAnova$CIupper <- tAnova$estimate + edt*tAnova$se 
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# Add Dunnett p.values 
dunnett <- glht(lm, linfct=mcp(treat="Dunnett")) 
tAnova$pdunnett <- summary(dunnett)$test$pvalues 
 
# Add SES and its confidence interval 
tAnova$SES <- tAnova$estimate/tAnova$seRes 
tAnova$SESlower <- NA * tAnova$SES 
tAnova$SESupper <- NA * tAnova$SES 
tnobs <- aggregate(response ~ treat, data=data, FUN=function(x) sum( !is.na(x) )) 
nobs  <- as.vector(tnobs[,2]) 
mult  <- sqrt( (nobs[1] + nobs[c(2,3,4,5)]) / (nobs[1]*nobs[c(2,3,4,5)]) ) 
for (ii in 1:4) { 
  CInct <- conf.limits.nct(tAnova$tvalue[ii], tAnova$dfRes[ii], conf.level=alpha) 
  tAnova$SESlower[ii] <- mult[ii] * CInct$Lower.Limit 
  tAnova$SESupper[ii] <- mult[ii] * CInct$Upper.Limit 
} 
 
# Do normality checks for lm() residuals 
# This is only approximate because residuals are not independent 
res <- residuals(lm) 
ks <- ks.test(res, "pnorm", mean(res), sd(res)) 
testStats["pKS","value"] <- ks$p.value 
sw <- shapiro.test(res) 
testStats["pSW","value"] <- sw$p.value 
 
# ================================================================================= 
# Non-parametric Friedman test and pairwise Wilcoxon signed rank tests 
# ================================================================================= 
fried <- friedman.test(data$response, groups=data$treat, blocks=data$block) 
testStats["pFriedmanAs","value"] <- fried$p.value 
 
if (fried$p.value < friedman.limit) { 
  blk <- as.numeric(data$block) 
  trt <- as.numeric(data$treat) 
  pFrd <- pFrd(x=data$response, b=blk, trt=trt, method="Monte Carlo", 
n.mc=friedman.mc) 
  testStats["pFriedmanMc","value"] <- pFrd$p.val 
} else { 
  testStats["pFriedmanMc","value"] <- NA 
} 
 
# Pairwise Wilcoxon signed rank test. Note that ordering of data is (block,treat) 
# Also note that wilcox.test() can handle NA 
sublevels <- levels(data$treat)[1] 
controlData <- data$response[data$treat %in% sublevels] 
for (ii in 1:4) { 
  sublevels <- levels(data$treat)[1+ii] 
  treatData <- data$response[data$treat %in% sublevels] 
  wt <- wilcox.test(controlData, treatData, paired=TRUE, exact=TRUE) 
  tPairwise$pwilcoxon[ii] <- wt$p.value 
} 
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# ================================================================================= 
# Bartlett test for homogeneity of variance 
# ================================================================================= 
bt <- bartlett.test(response ~ treat, data=data) 
testStats["pBartlett","value"] <- bt$p.value 
lv <- levene.test(response ~ treat, data=data, center=mean) 
testStats["pLeveneMean","value"] <- lv$'Pr(>F)'[1] 
lv <- leveneTest(response ~ treat, data=data, center=median) 
testStats["pLeveneMedian","value"] <- lv$'Pr(>F)'[1] 
 
# ================================================================================= 
# Kolomogorov-Smirnov & Shapiro-Wilks tests for normality 
# ================================================================================= 
normality <- as.data.frame(matrix(nrow=5,ncol=3)) 
colnames(normality) <- c("term", "pKS", "pSW") 
normality$term <- levels(data$treat) 
normality[, seq(2,ncol(normality))] <- NA 
for (ii in 1:5) { 
  sublevels <- levels(data$treat)[ii] 
  treatData <- data$response[data$treat %in% sublevels] 
  treatData <- treatData[!is.na(treatData)] 
  if (var(treatData) > 0) { 
    ks <- ks.test(treatData, "pnorm", mean(treatData), sd(treatData)) 
    normality$pKS[ii] <- ks$p.value 
    sw <- shapiro.test(treatData) 
    normality$pSW[ii] <- sw$p.value 
  } 
} 
 
# ================================================================================= 
# Output results for further processing in GenStat 
# ================================================================================= 
for (ii in 1:1) { 
  cat("\n") 
  print(testStats);  cat("\n\n") 
  print(tAnova);     cat("\n\n") 
  print(tPairwise);  cat("\n\n") 
  print(normality);  cat("\n\n") 
} 
write.csv(testStats, file="RscriptTest.csv",      row.names=FALSE, quote=FALSE) 
write.csv(tAnova,    file="RscriptAnova.csv",     row.names=FALSE, quote=FALSE) 
write.csv(tPairwise, file="RscriptPairwise.csv",  row.names=FALSE, quote=FALSE) 
write.csv(normality, file="RscriptNormality.csv", row.names=FALSE, quote=FALSE) 
 
